


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B 1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 239/62, 239/66, 401/04, A61K 31/515	A1	(11) International Publication Number: WO 97/23465 (43) International Publication Date: 3 July 1997 (03.07.97)
(21) International Application Number: PCT/EP96/05766 (22) International Filing Date: 20 December 1996 (20.12.96) (30) Priority Data: 195 48 624.2 23 December 1995 (23.12.95) DE (71) Applicant (for all designated States except US): BOEHRINGER MANNHEIM GMBH [DE/DE]; D-68298 Mannheim (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): BOSIES, Elmar [DE/DE]; Delpstrasse 11, D-69469 Weinheim (DE). ESSWEIN, Angelika [DE/DE]; Birkenweg 4, D-64572 Büttelbron (DE). GRAMS, Frank [DE/DE]; In den alten Wiesen 55, D-68219 Mannheim (DE). KRELL, Hans-Willi [AT/DE]; Zugspitzstrasse 14A, D-82377 Penzberg (DE). MENTA, Ernesto [IT/IT]; Boehringer Mannheim Italia S.p.A., Viale della Libertà, km 0,750, I-20052 Monza (IT). (74) Common Representative: BOEHRINGER MANNHEIM GMBH; Patentabteilung, D-68298 Mannheim (DE).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: NEW BARBITURIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS (57) Abstract Compounds of formula (I) in which X, Y and Z are independently of one another oxygen, sulphur or NH; R ₁ represents a group W-V: W is a valence dash or a straight-chained or branched C ₁ -C ₈ alkyl or a C ₂ -C ₈ alkenyl group which is optionally once or several times substituted, V is an optionally substituted monocycle or bicycle which can contain one or several heteroatoms, or W-V is a C ₁ -C ₂₀ alkyl group which can be interrupted by heteroatoms, one or several carbon atoms are optionally substituted; R ₂ and R ₃ represent hydrogen or one of the two represents lower alkyl or lower acyl; R ₄ and R ₅ denote independently of each other for A-D, wherein A represents a dash alkyl, alkenyl, acyl, alkylsulfonyl, sulfonyl, alkylaminocarbonyl, aminocarbonyl, alkoxycarbonyl, oxy-carbonyl, alkylaminothiocarbonyl, aminothio-carbonyl which is optionally once or several times substituted; D represents a hydrogen, monocycle or bicycle, the monocycle or bicycle is optionally once or several times interrupted by heteroatoms and the monocycle or bicycle is once or several times substituted, or R ₄ and R ₅ together with the adjacent N atom form a ring; pharmacologically acceptable salts and prodrugs thereof and optically active forms, processes for their production and pharmaceutical agents which contain these compounds having a matrix metalloprotease-inhibitory action.		



Best Available Copy

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5 **New barbituric acid derivatives, processes for their production and
pharmaceutical agents containing these compounds**

In normal tissue there is an equilibrium between synthesis and degradation. Extracellular
matrix is degraded by proteases which belong to at least three groups of matrix
10 metalloproteases. These are the collagenases, gelatinases and stromelysins. Normally
there are specific inhibitors for these catabolic enzymes such as α_2 macroglobulins and
MMP (= tissue inhibitor of metalloproteases (TIMP)) so that an excessive degradation of
extracellular matrix does not occur. A related group of proteases is the adamalysins. A
prominent member of the adamalysins is TACE (TNF- α -converting enzyme).

15 At least 11 different and yet highly homologous MMP species have been characterized,
including the interstitial fibroblast collagenase (MMP-1, HFC), the neutrophil
collagenase (MMP-8, HNC), two gelatinases, stromelysins (such as HSL-1) and
HPUMP (for a recent review, see Birkedal-Hansen, H., Moore, W.G.I., Bodden, M.K.,
20 Windsor, L.J., Birkedal-Hansen, B., DeCarlo, A., Engler, J.A., Critical Rev. Oral
Biol.Med. (1993) 4, 197-250. These proteinases share a number of structural and
functional features but differ somewhat in their substrate specificity. Only HNC and HFC
are capable of cleaving type I, II and III native triple-helical collagens at a single bond
25 collagen melting point and makes them accessible to further attack by other matrix
degrading enzymes.

However, the uncontrolled excessive degradation of this matrix is a characteristic of
many pathological states such as e.g. in the clinical picture of rheumatoid arthritis,
30 osteoarthritis, multiple sclerosis, in the formation of tumour metastases, corneal
ulceration, inflammatory diseases and invasion and in diseases of the bone and teeth.

It can be assumed that the pathogenesis of these clinical pictures can be favourably
influenced by the administration of matrix metalloprotease inhibitors. A number of
35 compounds in the meantime are known in the literature (see e.g. the review article of
Nigel RA Beeley et al. Curr. Opin. ther. Patents 4 (1), 7 (1994)) or are described in the
patent literature, these mainly being peptides with a hydroxamic acid residue, a thiol or


phosphine group as a zinc binding group (see e.g. WO-A-9209563 by Glycomed, EP-A-497 192 by Hoffmann-LaRoche, WO-A-9005719 by British Biotechnology, EP-A-489 577 by Celltech, EP-A-320 118 by Beecham, US-A-459 5700 by Searle among others).

- 5 Some of these compounds have a high activity as inhibitors of matrix metalloproteases but only have a very low oral availability.

It has now been found that the claimed new barbituric acid derivatives are very efficacious as matrix metallo-protease inhibitors and have a good oral availability.

10

The present invention therefore concerns substances of the general formula I



15 in which

X, Y and Z are independently of one another oxygen, sulphur or NH.

R₁ represents a group W-V

20

W is a valence dash or a straight-chained or branched C₁-C₈ alkyl or a C₂-C₈ alkenyl group which is optionally once or several times substituted,

V is an optionally substituted monocycle or bicycle which can contain one or several
25 heteroatoms,

or

W-V is a C₁-C₂₀ alkyl group which can be interrupted by heteroatoms, one or several carbon atoms are optionally substituted,

30 R₂ and R₃ represent hydrogen or one of the two represents lower alkyl or lower acyl

R₄ and R₅ denote independently of each other for A-D wherein A represents a dash, alkyl, alkenyl, acyl, alkylsulfonyl, sulfonyl, alkylaminocarbonyl, aminocarbonyl, alkoxycarbonyl, oxy-carbonyl, alkylaminothiocarbonyl, aminothio-carbonyl which is optionally once or several times substituted,

5

D represents a hydrogen, mono or bicycle, the monocycle or bicycle is optionally once or several times interrupted by heteroatoms and the monocycle or bicycle is once or several times substituted,

10 or

R₄ and R₅ together with the nitrogen atom to which they are bound represent a ring which optionally can be interrupted by a further N atom, said ring can be condensed to a monocycle or bicycle; said ring can optionally be substituted once or several times
15 independently by the residues hydroxy, alkoxy, amino, alkylamino, dialkylamino, nitril or by E-G wherein E represents a dash, alkyl, alkenyl, acyl, alkylsulfonyl, sulfonyl, alkylaminocarbonyl, aminocarbonyl, alkoxycarbonyl, oxy-carbonyl, alkylaminothiocarbonyl, aminothiocarbonyl which is optionally substituted; G represents a hydrogen, mono or bicycle, the monocycle or bicycle is optionally once or several times
20 interrupted by heteroatoms and the monocycle or bicycle is once or several times substituted,

pharmacologically acceptable salts or prodrugs thereof as well as the use of these
25 compounds to produce pharmaceutical agents.

The monocycle listed in the case of R₁, R₄ and R₅ is understood as saturated or unsaturated ring systems with 3 - 8, preferably 5 - 7 carbon atoms which can optionally be interrupted one or several times by heteroatoms such as nitrogen, oxygen or sulphur
30 in particular a cyclopentyl, cyclohexyl, cycloheptyl, morpholinyl, thiamorpholinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furyl, thiophenyl, imidazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl or 1,2,4-triazolyl residue. Lower alkyl, alkoxy and halogen come above all into consideration as substituents.

35

The bicycle listed under R_1 , R_4 and R_5 , is understood to be a condensed bicycle or a bicycle of the type monocycle₁-L-monocycle₂, wherein L denotes a valence dash C_1 - C_4 -alkyl group, C_2 - C_4 an alkenyl group, an oxygen or -C(O)-group.

- 5 The bicycle is preferably a residue such as a naphthyl, tetrahydronaphthyl, dekalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, indazolyl, oxindolyl, benzofuranyl, benzothiophenyl, benzthiazolyl, benzoxazolyl, purinyl, biphenyl or (4-phenoxy)phenyl residue and in particular a
10 naphthyl, biphenyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, indolyl or benzimidazolyl residue.

- The residues listed under R_1 , R_4 and R_5 can optionally be substituted once or several times by halogen, hydroxy, thio, alkyl, hydroxyalkyl, alkoxy, alkylthio, alkylsulfinyl, alkyl-sulfonyl, amino, alkylamino, dialkylamino, nitro, carboxyl, carboxamido, alkoxy-
15 carbonyl, amino or aminocarbonyl optionally substituted once or twice by lower alkyl, nitrile, oxo, thiocarboxamido, alkoxymethylcarbonyl, alkylmercaptocarbonyl, phosphono, alkylphosphono, dialkylphosphono, alkylsulfonylamido, arylamino, aryl, hetaryl, aryloxy, arylthio, arylsulfinyl, arylsulfonyl or acyl.

- 20 In this case the halogen, hydroxy, oxo, thio, alkoxy, alkylthio, amino, aminocarbonyl, carboxyl and acyl groups are preferred.

- Lower alkyl denotes C_1 - C_6 -Alkyl, preferred methyl, ethyl, propyl, isopropyl or tert.-butyl.
25

Lower acyl in the residues R_2 and R_3 above all denotes for -C(O)- C_1 - C_6 -alkyl or -C(O)H, preferred for an acetyl group.

- The alkyl residues in R_1 , R_4 and R_5 can optionally be interrupted once or several time by
30 heteroatoms (O, S, NH).

- Alkyl in the residues R_4 and R_5 denotes as such or in combination with alkoxy, alkylthio, arylsulfonyl, alkylsulfonyl, alkylaminocarbonyl, arylaminocarbonyl, alkylamino, alkoxy-carbonyl, aryloxy-carbonyl, alkylaminothiocarbonyl, arylaminothiocarbonyl a
35 straight-chained, branched, saturated or unsaturated residue with 1 - 11, preferably 1 - 8 carbon atoms such as e.g. a methyl, ethyl, propyl, pentyl, octyl, allyl, propargyl, 2,4-pentadienyl, isopropyl, sec. butyl, 3-methylbutyl, 2-hydroxyhexyl and in particular a

methyl, propyl, isopropyl, pentyl, octyl, allyl, 3-methylbutyl, 2-hydroxyhexyl and propargyl residue.

5 Aryl, also in combination with aryloxy, arylthio, arylsulfonyl, arylaminocarbonyl, aryloxycarbonyl, arylaminothiocarbonyl is understood as a phenyl or naphthyl residue which can optionally be substituted in particular by halogen, lower alkyl or alkoxy.

10 The C₁-C₂₀ alkyl group listed for R₁ is a straight-chained or branched saturated residue such as e.g. a methyl, ethyl, propyl, butyl, pentyl, octyl, decyl, undecyl, isobutyl, 3-methylbutyl or 7-methyloctyl group. Hydroxy and amino residues come above all into consideration as substituents. The alkyl chains can be interrupted once or several times by oxygen, nitrogen or sulphur. The preferred heteroatom interruption is oxygen (ether linkage) or -C(O)NH- (amid linkage). The most preferred heteroatom interrupted residues are -(CH₂CH₂O)_n-(CH₂)_mH and n = 2 or 3 and m = 1 or 2.

15

W of R₁ is preferably a methyl, ethyl, butyl or hexyl residue; V is in particular a phenyl, Pyridyl, imidazolyl residue which can optionally be substituted above all by lower alkyl, hydroxy, alkoxyamid, sulfonamide or halogen. The most preferred R₁ residues are C₆-C₁₂-Alkyl residue or a -(CH₂)_n-C₆H₄-(CH₂)_mH residue, wherein m and n are equal or
20 less than 8, the (CH₂)-group is optionally interrupted by oxygen, sulfur, or NH and one or two carbons of the phenyl ring are substituted for N-heteroatoms. The alkyl, aryl, hetaryl groups are optionally substituted by small polar substituents.

The most preferred R₁ residues are n-Octyl, n-Decyl, Biphenyl or octyl or decyl type
25 residues showing two or three oxygen heteroatoms like 2-(2-(2-methoxyethoxy)-ethoxy)ethyl, 2-(2-ethoxyethoxy)ethyl or biphenyl-type residues showing one or two nitrogen heteroatoms. The bridging monocycle is optionally ortho substituted and the terminal monocycle of the biphenyl or biphenyl type residue is optionally ortho or para substituted by a small, polar substituent like NH₂, -NO₂, -SO₂NH₂, SO₂CH₃, Acetyl,
30 Hydroxy, Methoxy, Ethoxy or Nitril-group. The para substitution of the terminal monocycle is more preferred.

Halogen is understood as chlorine, bromine, iodine and preferably chlorine.

35 The hetaryl residues listed for R₄ and R₅ denote preferred for a pyridine, pyrazine, piperazine, imidazole, thiazole, thiophene or indole ring preferably a pyridine, imidazole and thiophene ring.

The acyl residue listed for the residues R₄ and R₅ is a residue with 1 - 10, preferably 6 - 8 carbon atoms such as e.g. a hexanoyl or octanoyl residue. The alkyl group can be interrupted once or several times by heteroatoms or heteroatom groups like S, O, NH, SO₂, amido or carbonyl. These residues can be substituted by amino groups, alkyl groups, aryl groups, arylalkyl groups, alkylamino groups, dialkylamino groups, alkoxy groups and aromatic compounds. These are then amino acid residues preferably a phenylalanine and tryptophan residue in this case.

If R₄ and R₅ form a ring together with the nitrogen atom to which they are bound, these are 5 - 7-membered rings preferably a six-membered ring. The piperidine, piperazine, tetrahydroquinoline and tetrahydroiso-quinoline, bicyclo(9.4.0)pentadecyl and 1,2,3,4-tetrahydrobenzo(g)isoquinoline rings are preferred.

If compounds of the general formula I contain one or several asymmetric carbon atoms, the optically active compounds of the general formula I are also a subject matter of the present invention.

Independently of each other the preferred meaning for X, Y, Z is oxygen, for R₂ and R₃ it is hydrogen. A more preferred combination is X, Y and Z equal each oxygen and R₂ is identical to R₃ and both mean hydrogen.

It is also preferred that R₄ and R₅ do not both represent hydrogen.

The term "several" means in connection with heteroatoms in monocycles or bicycles preferred one, two or three more preferred one or two, the most preferred heteroatom is nitrogen.

The term "several" means in connection with substituents or substitution preferred one to five, more preferred one, two or three most preferred one or two.

The term "heteroatom" in connection with alkyl or acyl groups means preferred oxygen or NH, more preferred oxygen.

Substitutions of monocycles or bicycles in R₁, R₄ and R₅ are halogen, nitro, hydroxy, alkoxy, amino, alkylamino, dialkylamino, halogenmethyl, dihalogenmethyl, trihalogenmethyl, phosphono, alkylphosphono, dialkylphosphono, SO₂NH₂, SO₂NH(alkyl), SO₂N(alkyl)₂, SO₂(alkyl), acetyl, formyl, nitril, COOH, COOalkyl, -OC(O)alkyl, -NHC(O)Oalkyl, OC(O)O-aryl, -NHC(S)NH₂, -NHC(S)NHalkyl, -NHC(O)-aryl.

The preferred ring structure formed together with the nitrogen, R_4 and R_5 , is piperazin or piperidin, both of which are substituted preferably at the 4-position. In the case of piperidin the 4 position is optionally substituted by a second substitute hydroxy, amino, alkylamino, dialkylamino or alkoxy. The 4 position of piperidin may also
5 form a double bond with the substituent of the 4 position.

Preferred substitution of the 4 position of piperidin or piperazin are 6-membered aromatic monocycles which are more preferred substituted in para position by small polar substitutions as hydroxy, lower alkoxy, amino, lower alkylamino, lower
10 dialkylamino, nitro, nitrilo, SO_2NH_2 , SO_2NH lower alkyl, SO_2 lower alkyl. The 6 membered aromatic monocycle is preferably bound to the 4 position via a valence bond or a lower alkyl spacer.

In the case that R_4 is hydrogen a lower alkyl a lower alkylaryl, then R_5 is preferred a acyl
15 derivate preferably substituted with a monocycle or lower alkylaryl; or a $-CHR_{50}-CHR_{51}-NR_{52}-R_{53}$ wherein R_{50} and R_{51} denote independently of each other for hydrogen, lower alkyl a lower alkoxy. R_{52} denotes for hydrogen or lower alkyl, R_{53} denotes a 6-membered aromatic monocycle which is optionally once or several times substituted and bound to the nitrogen preferably via a valence bond or a lower alkyl spacer.


20

The most preferred combination of meanings in general formula I are
X equals Y equals Z equals oxygen and
 R_2 equals R_3 equals hydrogen and
 R_1 equals n-Octyl, n-Decyl, Biphenyl or octyl or decyl type residues showing two or
25 three oxygen heteroatoms like 2-(2-(2-methoxyethoxy)-ethoxy)ethyl, 2-(2-ethoxyethoxy)ethyl or biphenyl-type residues showing one or two nitrogen heteroatoms; wherein the bridging monocycle is optionally ortho substituted and the terminal monocycle of the biphenyl or biphenyl type residue is optionally ortho or preferred para substituted by a small, polar substituent like NH_2 , $-NO_2$, $-SO_2NH_2$, SO_2CH_3 , Acetyl,
30 Hydroxy, Methoxy, Ethoxy or Nitril-group and
 R_4 and R_5 form together with the nitrogen to which they are bound a piperazin or piperidin both of which are substituted in the 4 position with a phenyl, pyridyl or pyrazidyl ring which is preferred para substituted by a small polar substituent; in the case of piperidin the 4 position may be additionally substituted by hydroxy, lower alkoxy, nitril
35 or amin which may be mono- or disubstituted by lower alkyl.


Compounds of the general formula I can be synthesized by well-known processes preferably in that

a) compounds of the general formula II

5



10 in which X, Y, Z, R₁, R₂ and R₃ have the above-mentioned meanings and T represents a leaving group such as Hal or OSO₂R₆, Hal denoting chlorine, bromine or iodine and R₆ denoting an aryl or a methyl residue, are reacted with a compound of the general formula III




15


in which R₄ and R₅ have the meanings stated above and optionally converted into pharmacologically acceptable salts or

b) compounds of the general formula IV

20



25 in which R₁, R₄ and R₅ have the above-mentioned meanings, Y and Z independently of one another represent oxygen, sulphur or a NH group and R₇ = methyl, ethyl or phenyl, is reacted with a compound of the general formula V



in which R₂, R₃ and X have the above-mentioned meanings and optionally converted into pharmacologically acceptable salts


5

or

in the case that R₄ and/or R₅ represent an acyl, alkylsulfonyl, arylsulfonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminothiocarbonyl or arylaminothiocarbonyl residue


10

c) a compound of the general formula VI



15

in which X, Y, Z, R₁, R₂ and R₃ have the above-mentioned meanings, is reacted with a compound of the general formula VII or VIII



20

in which R₈ represents an optionally substituted alkyl or aryl residue, D = C(O), O-C(O), SO₂ or a valency dash. Hal = chlorine, bromine or iodine and A represents oxygen or sulphur

25

and optionally converted into pharmacologically acceptable salts.

Compounds of the general formula II are known in the literature. Thus for example 2,4,6-pyrimidine triones brominated in the 5-position can be synthesized by reacting the appropriate bromomalonic acid dialkyl esters with urea (e.g. Acta Chim. Acad. Sci. Hung. 107 (2), 139 (1981)). The corresponding brominated or chlorinated compounds of the general formula II can be obtained by reacting 2,4,6-pyrimidine-triones substituted by

30

R₁ in the 5-position with bromine (analogous to J. pr. Chemie 136, 329 (1933) or J. Chem. Soc. 1931, 1870) or sulfonyl chloride (J. Chem. Soc. 1938, 1622). In the same manner one can synthesize the 2-imino-4,6-pyrimidine-diones of the general formula II correspondingly halogenated in the 5-position analogously to Collect. Czech. Comm. 48 (1), 299 (1933). The reaction of 2-thia-4,6-pyrimidine-diones substituted by R₁ in the 5-position with bromine in glacial acetic acid (analogously to Am. Chem. J. 34, 186) leads to the compounds of the general formula II correspondingly brominated in the 5-position.

10 Amines of the general formula III are commercially available or are usually known in the literature.

Compounds of the general formula IV are reacted according to known methods with ureas (see for example J. Med. Chem. 10, 1078 (1967) or Helvetica Chim. Acta 34, 459 (1959) or Pharmacie 38 (1), 65 (1983)), thioureas (see for example Indian J. Chem. 24 (10), 1094 (1985) or J. Het. Chem. 18 (3), 635 (1981)) or guanidines (see for example Collect. Czech. Chem. Comm. 45 (12), 3583 (1980)) of the general formula V.

20 The reactions are usually carried out in an alcohol such as methanol, ethanol or butanol in the presence of an appropriate sodium alcoholate at temperatures between 40°C and 100°C and in the case of the guanidines also at temperatures of up to 200°C (under pressure). In the case of the thioureas the process is frequently carried out in the presence of acetyl chloride (also as a solvent).

25 Compounds of the general formula IV are known from the literature or can be produced according to processes known from the literature. They can be synthesized for example by weak acidic hydrolysis of the corresponding bislactim ethers (see J. Chem. Soc. Chem. Comm. 5, 400 (1990)). Other methods of synthesis are for example described in Farmaco Ed. Sci. 31 (7), 478 (1976) or Aust. J. Chem., 23 (6), 1229 (1970).

30 Ureas, thioureas and guanidines of the general formula V are commercially available.

Compounds of the general formula VI can easily be synthesized by reacting an appropriate substituted acetamidomalonic ester according to process b) and subsequent hydrolytic cleavage of the acetyl group (see Can. J. Chem. 42 (3), 605 (1964)).

Carboxylic acid chlorides of the general formula VII are known or can be synthesized by generally known methods from the corresponding carboxylic acids. The reaction is usually carried out with thionyl chloride or phosphorus tribromide or phosphorus pentabromide or pentachloride in inert solvents such as dichloromethane, diethyl ether, dioxane or tetrahydrofuran at temperatures of 0°C to 50°C, preferably between 20°C and 40°C.

Chloroformic acid esters of the general formula VII are known in the literature or can be obtained by generally known methods from the corresponding alcohols by reaction with phosgene or diphosgene. The reaction proceeds in inert solvents such as e.g. diethyl ether, dichloromethane, dioxane, tetrahydrofuran or toluene at temperatures between -20°C and 20°C. In the case of phosgene the reaction is carried out in the presence of bases, usually tertiary amines such as e.g. triethylamine or pyridine.

Sulfonic acid chlorides of the general formula VII are known or can be synthesized analogously to described methods from the corresponding sulfonic acids by reaction with phosphorus pentachloride or thionyl chloride. The reaction is usually carried out in an inert solvent such as e.g. dimethylformamide or also without a solvent at temperatures of 20°C to 180°C, preferably at 50°C to 100°C.

Isocyanates of the general formula VIII are known or can be synthesized by methods known in the literature. Thus for example appropriate alkyl halogenides of the general formula $R_8\text{-Hal}$ can be reacted with potassium cyanate analogously to Synthesis 1978, 760. Further methods are to react an acid amide of the general formula $R_8\text{-CONH}_2$ with oxalyl chloride, to thermally decompose an acid azide of the general formula $R_8\text{-CON}_3$ or to react an amine of the general formula $R_8\text{-NH}_2$ with phosgene (analogously to Ann. Chem. 562, 110).

Isothiocyanates of the general formula VIII are known in the literature or can be synthesized analogously to known processes. An amine of the general formula $R_8\text{-NH}_2$ is preferably allowed to react with carbon disulphide under alkaline conditions analogously to Chem. Ber. 74, 1375.

The reaction of carboxylic acid halogenides, sulfonic acid halogenides or chloroformic acid esters of the general formula VII with amines of the general formula VI is usually carried out in a solvent such as dichloromethane, dimethylformamide or pyridine with

addition of an auxiliary base such as triethylamine or 4-dimethylaminopyridine at a temperature between -10°C and 50°C, preferably at room temperature.

Compounds of the general formula I can contain one or several chiral centres and can then be present in a racemic or in an optically active form. The racemates can be separated according to known methods into the enantiomers. Preferably diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid or with an optically active amine such as e.g. D- or L- α -phenyl-ethylamine, ephedrine, quinidine or cinchonidine.

Alkaline salts, earth alkaline salts like Ca or Mg salts, ammonium salts, acetates or hydrochlorides are mainly used as pharmacologically acceptable salts which are produced in the usual manner e.g. by titrating the compounds with inorganic or organic bases or inorganic acids such as e.g. sodium hydroxide, potassium hydroxide, aqueous ammonia, C₁-C₄-alkyl-amines such as e.g. triethylamine or hydrochloric acid. The salts are usually purified by reprecipitation from water/acetone.

The new substances of formula I and salts thereof according to the invention can be administered enterally or parenterally in a liquid or solid form. In this connection all the usual forms of administration come into consideration such as for example tablets, capsules, coated tablets, syrups, solutions, suspension etc. Water which contains additives such as stabilizers, solubilizers and buffers that are usual in injection solutions is preferably used as the injection medium.

Such additives are e.g. tartrate and citrate buffer, ethanol, complexing agents (such as ethylenediaminetetra-acetic acid and non-toxic salts thereof), high-molecular polymers (such as liquid polyethylene oxide) to regulate viscosity. Liquid carrier substances for injection solutions have to be sterile and are preferably dispensed into ampoules. Solid carrier substances are e.g. starch, lactose, mannitol, methylcellulose, talcum, highly dispersed silicic acids, higher molecular fatty acids (such as stearic acid), gelatins, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high-molecular polymers (such as polyethylene glycols); suitable preparations for oral application can optionally also contain flavourings and sweeteners.

The dosage can depend on various factors such as manner of administration, species, age and/or individual state of health. The doses to be administered daily are about 10-1000

mg/human, preferably 100-500 mg/human and can be taken singly or distributed over several administrations.

5 Prodrugs of the compounds of the invention are such which are converted in vivo to the pharmacological active compound. The most common prodrugs are carboxylic acid esters.

10 Within the sense of the present invention the following barbituric acid derivatives are preferred in addition to the compounds mentioned in the examples and compounds that can be derived by combining all meanings of substituents mentioned in the claims:

1. 5-(N-benzyl-N-octyl)-5-phenyl-barbituric acid
2. 5-(N-benzyl-N-phenethyl)-5-phenyl-barbituric acid
3. 5-(N-benzyl-N-[2-(4-pyridyl)ethyl])-5-phenyl-barbituric acid
- 15 4. 5-(N-benzyl-N-[2-(3-pyridyl)ethyl])-5-phenyl-barbituric acid
5. 5-(N-benzyl-N-[2-(2-pyridyl)ethyl])-5-phenyl-barbituric acid
6. 5-(N-benzyl-N-[2-(2-thiophenyl)ethyl])-5-phenyl-barbituric acid
7. 5-[N-(3-methylbutyl)-N-(3-phenylpropyl)]-5-phenyl-barbituric acid
8. 5-(N-benzyl-N-[3-(4-pyridyl)propyl])-5-phenyl-barbituric acid
- 20 9. 5-(N-benzyl-N-[2-(2-imidazolyl)ethyl])-5-phenyl-barbituric acid
10. 5-(N-benzyl-N-[2-(1-imidazolyl)ethyl])-5-phenyl-barbituric acid
11. 5-(N-butyl-N-phenylalaninyl)-5-phenyl-barbituric acid
12. 5-(N-butyl-N-tryptophanyl)-5-phenyl-barbituric acid
13. 5-(N-benzyl-N-cyclohexyl)-5-phenyl-barbituric acid
- 25 14. 5-[N-benzyl-N-(2-pyridyl)]-5-phenyl-barbituric acid
15. 5-[N-butyl-N-(4-piperidinyl)]-5-phenyl-barbituric acid
16. 5-[N-benzyl-N-(2-imidazolyl)]-5-phenyl-barbituric acid
17. 5-(N-octyl-N-phenyl)-5-phenyl-barbituric acid
18. 5-[N-(2-naphthyl)-N-propyl]-5-phenyl-barbituric acid
- 30 19. 5-[N-(4-tetrahydroquinoliny)]-N-propyl]-5-phenyl-barbituric acid
20. 5-[N-benzyl-N-(2-thiophenyl)]-5-phenyl-barbituric acid
21. 5-[N-(3-methylbutyl)-N-[3-(4-pyridyl)propyl]]-5-phenyl-barbituric acid
22. 5-[N-(7-methyloctyl)-N-[3-(2-pyridyl)propyl]]-5-phenyl-barbituric acid
23. 5-(N-(2-hydroxyhexyl)-N-[3-(3-pyridyl)propyl])-5-phenyl-barbituric acid
- 35 24. 5-(N-benzyl-N-hexanoyl)-5-phenyl-barbituric acid
25. 5-(N-benzyl-N-octanoyl)-5-phenyl-barbituric acid
26. 5-(N-benzyl-N-octanesulfonyl)-5-phenyl-barbituric acid

27. 5-[N-butyl-N-(2-naphthylsulfonyl)]-5-phenyl-barbituric acid
28. 5-(N-hexyloxycarbonyl-N-propyl)-5-phenyl-barbituric acid
29. 5-(N-(4-methoxy-phenylsulfonyl)-N-hexyl)-5-phenyl-barbituric acid
30. 5-[N-(4-butoxy-phenylsulfonyl)]-N-hexyl]-5-phenyl-barbituric acid
5 31. 5-[N-benzyl-N-(2-phenethyl)]-5-(4-pyridyl) barbituric acid
32. 5-[N-benzyl-N-(2-phenethyl)]-5-(2-pyridyl) barbituric acid
33. 5-(N,N-dipentyl)-5-(4-piperidiny)barbituric acid
34. 5-(N,N-dioctyl)-5-(2-thiophenyl)barbituric acid
35. 5-(N-benzyl-N-[2-(2-pyridyl)ethyl]-5-(3-imidazolyl) barbituric acid
10 36. 5-[1-(4-hydroxy)piperidiny]-5-(4-pyridyl) barbituric acid
37. 5-[1-(4-hydroxy)piperidiny]-5-(3-pyridyl) barbituric acid
38. 5-[1-(4-hydroxy)piperidiny]-5-(2-pyridyl) barbituric acid
39. 5-[1-(4-hydroxy)piperidiny]-5-(4-piperidiny) barbituric acid
40. 5-[1-(4-hydroxy)piperidiny]-5-(2-thiophenyl) barbituric acid
15 41. 5-[1-(4-hydroxy)piperidiny]-5-(4-imidazolyl) barbituric acid
42. 5-benzyl-5-[1-(4-hydroxy)piperidiny]barbituric acid
43. 5-[1-(4-hydroxy)piperidiny]-5-(2-phenethyl) barbituric acid
44. 5-[1-(4-hydroxy)piperidiny]-5-(1-naphthyl) barbituric acid
45. 5-[1-(4-hydroxy)piperidiny]-5-(2-naphthyl) barbituric acid
20 46. 5-(2-quinoliny)-5-[1-(4-hydroxy)piperidiny] barbituric acid
47. 5-[1-(4-hydroxy)piperidiny]-5-(1-isoquinoliny) barbituric acid
48. 5-[1-(4-hydroxy)piperidiny]-5-(2-tetrahydro-quinoliny)barbituric acid
49. 5-(2-indolyl)-5-[1-(4-hydroxy)piperidiny] barbituric acid
50. 5-(2-benzimidazolyl)-5-[1-(4-hydroxy)piperidiny] barbituric acid
25 51. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-octyl-barbituric acid
52. 5-decyl-5-(1-[4-(2-hydroxyethyl)piperazinyl]) barbituric acid
53. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-undecyl-barbituric acid
54. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(7-methyl-octyl)barbituric acid
55. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(8-hydroxy-octyl)barbituric acid
30 56. 5-(8-amino-octyl)-5-(1-[4-(2-hydroxyethyl) piperazinyl])barbituric acid
57. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(2-phen-ethyl)barbituric acid
58. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(4-phenyl-butyl)barbituric acid
59. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(6-phenyl-hexyl)barbituric acid
60. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-[6-(4-methylphenyl)hexyl]barbituric
35 acid
61. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(2-pyridylmethyl)barbituric acid
62. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(4-imidazolylmethyl)barbituric acid

63. 5-(1-[4-(2-hydroxyethyl)piperazinyl])-5-(1-imidazolylmethyl)barbituric acid
64. 5-phenyl-5-(1-(4-propyl)piperazinyl)barbituric acid
65. 5-phenyl-5-(1-tetrahydroquinoliny)barbituric acid
66. 5-phenyl-5-(1-tetrahydroisoquinoliny)barbituric acid
5 67. 5-phenyl-5-[2-(1,2,3,4-tetrahydrobenzo(g)iso-quinoliny)]barbituric acid
68. 5-[2-(2-aza-bicyclo[9.4.0]pentadecyl)]-5-phenyl-barbituric acid
69. 5-[2-(2,11-diaza-12-oxo-bicyclo[9.4.0]pentadecyl)]-5-phenyl-barbituric acid
70. 5-(1-[4-(1-oxo-propyl)]piperidinyl)-5-phenyl-barbituric acid
71. 5-[1-(3-oxo-4-propyl)]piperidinyl]-5-phenyl-barbituric acid
10 72. 5-phenyl-5-[1-(4-propyl)piperazinyl]barbituric acid
73. 5-[1-(3,5-dihydroxy-4-propyl)piperidinyl]-5-phenyl-barbituric acid
74. 5-(4-chlorophenyl)-5-[1-(4-hydroxy)piperidinyl] barbituric acid
75. 5-(4-chlorobenzyl)-5-[1-(4-hydroxy)piperidinyl] barbituric acid
76. 5-[1-(4-hydroxy)piperidinyl]-5-(4-methoxybenzyl) barbituric acid
15 77. 3-methyl-5-[1-(4-hydroxy)piperidinyl]-5-phenyl-barbituric acid
78. 1-isopropyl-5-[1-(4-hydroxy)piperidinyl]-5-phenyl-barbituric acid
79. 3-acetyl-5-[1-(4-hydroxy)piperidinyl]-5-phenyl-barbituric acid
80. 5-[1-(4-methoxy)piperidinyl]-5-phenyl-2-thio-barbituric acid
81. 2-imino-5-[1-(4-methoxy)piperidinyl]-5-phenyl-barbituric acid
20 82. 5-[1-(4-methoxy)piperidinyl]-5-phenyl-2,4,6-triimino-barbituric acid
83. 4,6-diimino-5-[1-(4-methoxy)piperidinyl]-5-phenyl-barbituric acid
84. 5-[1-(4-methoxy)piperidinyl]-5-phenyl-2,4,6-trithio-barbituric acid
85. 5-(6-aminohexyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid
86. 5-(6-formylaminohexyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid
25 87. 5-(6-acetylaminohexyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid
88. 5-[7-(ethoxycarbonyl)heptyl]-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid
89. 5-(8-hydroxyoctyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid
90. 5-(7-carboxyheptyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid
91. 5-[7-(aminocarbonyl)heptyl]-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid
30 92. 5-[3-((aminocarbonylmethyl)aminocarbonyl)propyl]-5-[N-(2-hydroxyethyl)-
piperazinyl]barbituric acid
93. 5-[6-(methylamino)hexyl]-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid
94. 5-[4-(n-propyloxy)butyl]-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid
95. 5-[2-(2-(2-methoxyethoxy)ethoxy)ethyl]-5-[N-(4-
35 nitrophenyl)piperazinyl]barbituric acid
96. 5-[2-(2-(ethoxy)ethoxy)ethyl]-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid
97. 5-decyl-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid

98. 5-octyl-5-[N-(4-(hydroxysulphonyl)phenyl)piperazinyl]barbituric acid
99. 5-octyl-5-[N-(4-(aminosulphonyl)phenyl)piperazinyl]barbituric acid
100. 5-octyl-5-[N-(4-cyanophenyl)piperazinyl]barbituric acid
101. 5-octyl-5-[N-(4-carboxyphenyl)piperazinyl]barbituric acid
- 5 102. 5-octyl-5-[N-(4-(butoxycarbonyl)phenyl)piperazinyl]barbituric acid
103. 5-octyl-5-[N-(4-(amidino)phenyl)piperazinyl]barbituric acid
104. 5-octyl-5-[N-(4-(aminothiocarbonyl)phenyl)piperazinyl]barbituric acid
105. 5-octyl-5-[N-(4-(methylsulphonyl)phenyl)piperazinyl]barbituric acid
106. 5-octyl-5-[N-(4-(aminocarbonyl)phenyl)piperazinyl]barbituric acid
- 10 107. 5-octyl-5-[N-(4-(methylcarbonyl)phenyl)piperazinyl]barbituric acid
108. 5-octyl-5-[N-(4-(dimethylphosphonyl)phenyl)piperazinyl]barbituric acid
109. 5-octyl-5-[N-(4-(amino)phenyl)piperazinyl]barbituric acid
110. 5-octyl-5-[N-(4-(acetylamino)phenyl)piperazinyl]barbituric acid
111. 5-octyl-5-[N-(4-(trifluoroacetyl amino)phenyl)piperazinyl]barbituric acid
- 15 112. 5-octyl-5-[N-(4-(methylsulphonylamino)phenyl)piperazinyl]barbituric acid
113. 5-octyl-5-[N-(5-nitropyrid-2-yl)piperazinyl]barbituric acid
114. 5-octyl-5-[N-(N-oxypyrid-4-yl)piperazinyl]barbituric acid
115. 5-octyl-5-[N-(4-(5-triazolyl)phenyl)piperazinyl]barbituric acid
116. 5-octyl-5-[(N-benzoyl-N-benzyl)amino]barbituric acid
- 20 117. 5-[4-(phenyl)phenyl]-5-[(N-benzoyl-N-benzyl)amino]barbituric acid
118. 5-(4-[4-Nitrophenyl)piperazinyl])-5-octyl-barbituric acid
119. N-Benzyl-3-(4-nitro-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acrylamide
120. 5-[4-(phenyl)phenyl]-5-[(N-benzoyl-N-benzyl)amino]-barbituric acid
- 25 121. N-Benzyl-2-(3-bromo-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acetamide

Example 1

5-(1-[4-(2-Hydroxyethyl)piperazinyl])-5-phenyl-barbituric acid

- 30 5-Bromo-5-phenyl barbituric acid (Acta Chim. Acad. Sci. Hung. 107 139-45 (1981)) (7 mmol) and N-(2-hydroxy-ethyl)-piperazine (8 mmol) are suspended in 40 ml absolute ethanol. After 3 hours under reflux it is concentrated in a vacuum. The residue is purified by chromatography on silica gel (ethyl acetate/methanol 3:1). Colourless crystals are obtained by recrystallization from isopropanol. Yield 56 %; Fp. 238-40°C (decomp.).

Example 25-(1-[4-(4-Methylphenyl)methyl]piperazinyl)-5-phenyl-barbituric acid

5 5-Bromo-5-phenyl-barbituric acid (7 mmol) and N-(methyl-p-tolyl)-piperazin (8 mmol) are suspended in 40 ml absolute ethanol. After 2 hours under reflux it is concentrated in a vacuum. The residue is triturated with diethyl ether, sucked off, rewashed with 20 ml diethyl ether and dried. The crude product is purified by chromatography on silica gel (acetone). One obtains colourless crystals. Yield 72 %; Fp. 247-48°C.

Example 3

10 5-(1-[4-(4-(4-Methylphenyl))butyl]piperazinyl)-5-phenyl-barbituric acid

4-(p-Tolyl)-butyl bromide

15 The compound is prepared analogously to the literature. Synth. Commun. 22(20)2945-8 (1992). Yield 91 % colourless oil.

Phenyl-(4-(p-tolyl)-butyl)-malonic acid diethyl ester

20 Phenylmalonic acid diethyl ester (8.8 mmol) dissolved in 5 ml absolute tetrahydrofuran is added dropwise to 20 ml absolute tetrahydrofuran and sodium hydride (9.7 mmol). Then 4-p-tolylbutyl bromide (8.8 mmol) dissolved in 10 ml absolute tetrahydrofuran is added after 15 minutes. It is heated for 3 days under reflux. The solvent is concentrated in a vacuum. The residue is taken up in 50 ml ethyl acetate and extracted with 2 x 50 ml water. The organic phase is dried over magnesium sulfate, filtered and concentrated by
25 evaporation. It is purified by chromatography on silica gel (heptane/ethyl acetate 9:1). Yield 55 % colourless oil.

5-1-[4-(4-(4-methylphenyl))butyl]piperazinyl)-5-phenyl-barbituric acid

30 Urea (4.6 mmol) and phenyl-(4-(p-tolyl)-butyl)-malonic acid diethyl ester (3.1 mmol) are added to a solution of sodium ethylate (6.2 mmol) in absolute ethanol. It is heated for 12 hours under reflux, then concentrated in a vacuum and the residue is taken up in 15 ml water. The mixture is adjusted to pH 1-2 with 6 N hydrochloric acid and extracted with 2 x 30 ml ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and concentrated by evaporation. The residue is purified by chromatography on silica gel
35 (heptane/ethyl acetate 3:1). Yield 46 % colourless crystals; Fp. 163-5°C.

Example 45-(1-[4-(2-Hydroxyethyl)piperidinyl])-5-phenyl-barbituric acid

14.6 g (50 mmol) phenylmalonic acid diethyl ester and subsequently 10 g (166 mmol) urea are slowly added to 1.3 g sodium in 40 ml methanol while stirring. It is heated for 2 hours while slightly boiling. In this process a precipitate forms. It is cooled to 10-15°C, subsequently slowly admixed with 12.9 g (100 mmol) 4-(2-hydroxyethyl)piperidine, 13.8 g (100 mmol) potassium carbonate and 2.87 ml (112.3 mmol) bromine. The mixture is stirred for 2 hours at 10-15°C, then slowly heated to boiling and boiled for 1 hour under reflux. After cooling it is poured onto 240 ml 1N nitric acid, the solution is washed once with toluene and neutralized with a saturated sodium acetate solution. A greasy mass precipitates which is taken up in hot ethanol. The hot solution is treated with active carbon and admixed with warm water until turbidity starts. After cooling the crystals are suction filtered. Yield: 7.3 g = 44 %; Fp.: 222-223°C.

Example 55-Phenyl-5-(1-piperidinyl)barbituric acid

5-Phenyl-5-(1-piperidinyl)barbituric acid in a yield of 92 %; Fp.: 244-246°C is obtained analogously to example 4 using piperidine instead of 4-(2-hydroxyethyl) piperidine.

Example 65-[1-(4-Hydroxy)piperidinyl]-5-phenyl-barbituric acid

5-[1-(4-Hydroxy)piperidinyl]-5-phenyl-barbituric acid in a yield of 39 %; Fp.: 241-242°C (from ethanol) is obtained analogously to example 4 using 4-hydroxy-piperidine instead of 4-(2-hydroxyethyl)piperidine.

Example 75-[1-(4,4-Dimethyl)piperidinyl]-5-phenyl-barbituric acid

5-[1-(4,4-Dimethyl)piperidinyl]-5-phenyl-barbituric acid in a yield of 69 %; Fp.: 238-240°C (from ethanol/water) is obtained analogously to example 4 using 4,4-dimethyl-piperidine instead of 4-(2-hydroxyethyl)piperidine.

Example 85-[1-(4-Methyl)-piperidinyl]-5-phenyl-barbituric acid

5-[1-(4-Methyl)piperidinyl]-5-phenyl-barbituric acid in a yield of 87 %; Fp.: 208-209°C (from methanol/water) is obtained analogously to example 4 using 4-methyl-piperidine instead of 4-(2-hydroxyethyl)piperidine.

Example 95-[1-(4-Methoxy)piperidinyl]-5-phenyl-barbituric acid

5-[1-(4-Methoxy)piperidinyl]-5-phenyl-barbituric acid in a yield of 67 %; Fp.: 184-185°C (from ethanol/water) is obtained analogously to example 4 using 4-methoxy-piperidine instead of 4-(2-hydroxyethyl) piperidine.

Example 105-Ethyl-5-[1-(4-methyl)piperidinyl]barbituric acid

14.1 g (75 mmol) ethylmalonic acid diethyl ester and subsequently 15 g (264 mmol) urea is slowly added to 1.95 g sodium in 60 ml methanol while stirring. After boiling for 2 hours a precipitate forms. It is cooled to 10-15°C and successively slowly admixed with 15 g (15 mmol) 4-methylpiperidine, 21 g (150 mmol) potassium carbonate and 4.3 ml (168 mmol) bromine. The mixture is stirred for 2 hours at this temperature, slowly heated to boiling and heated for 1 hour under reflux. After cooling it is poured onto 360 ml 1 N nitric acid, the solution is washed once with toluene and admixed with an excess of saturated sodium acetate solution. The precipitated precipitate is recrystallized from ethanol with addition of active carbon. Yield: 4.4 g = 23 %; Fp.: 194-195°C.

Example 115-Ethyl-5-[1-(4-methoxy)piperidinyl]barbituric acid

5-Ethyl-5-[1-(4-methoxy)piperidinyl]barbituric acid in a yield of 15 %; Fp.: 201-202°C (from ethanol) is obtained analogously to example 10 using 4-methoxypiperidine instead of 4-methylpiperidine.

Example 125-Ethyl-5-[1-(4-hydroxy)piperidinyl]barbituric acid

5-Ethyl-5-[1-(4-hydroxy)piperidinyl]barbituric acid in a yield of 5 %; Fp.: 110-112°C (from ethanol) is obtained analogously to example 10 when using 4-hydroxypiperidine instead of 4-methoxypiperidine.

Example 135-Ethyl-5-[1-(4-(2-hydroxyethyl)piperidinyl)]barbituric acid

5-Ethyl-5-[1-(4-(2-hydroxyethyl)piperidinyl)]barbituric acid in a yield of 17 %; Fp.: 238-240°C (from methanol) is obtained analogously to example 10 using 4-(2-hydroxyethyl)piperidine instead of 4-methylpiperidine.

Example 14**5-(4-methoxyphenyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid**

a) preparation of ethyl 4-methoxyphenylacetate

5 A solution of 4-methoxyphenylacetic acid (2 g) and para-toluensulfonic acid (230 mg) in 30 ml of ethanol is refluxed for 2 hours. The solvent is evaporated under reduced pressure and the residue is suspended in a saturated aqueous solution of sodium hydrogencarbonate and extracted twice with ethyl acetate. The organic extracts are collected, washed with water and dried over sodium sulfate to give, after evaporation of
10 the solvent under reduced pressure, 2.14 g of the product.

b) preparation of ethyl 4-methoxyphenyl malonate

A mixture of ethyl 4-methoxyphenylacetate (27.8 g) and sodium (3.68 g) in 90 ml of diethylcarbonate is refluxed for 3 hours, then the solvent is evaporated under reduced
15 pressure and the residue is diluted with water and neutralized with acetic acid. The aqueous phase is extracted twice with diethyl ether. The organic extracts are pooled and washed twice with 1 N sodium hydroxide and once with water, then the organic phase is dried over sodium sulfate and concentrated to dryness. 34.2 g of the product are
20 obtained.

c) preparation of 5-(4-methoxyphenyl)barbituric acid

To a solution of 660 mg of sodium in 50 ml of ethanol are added 3.86 g of ethyl 4-methoxyphenyl malonate and 1.28 g of urea. The reaction mixture is refluxed for 3
25 hours. A white solid separates, which is collected by filtration and redissolved in 15 ml of water. The solution is acidified to pH = 1-2 by adding 6 N hydrochloric acid. A white solid separates, which is filtered and washed on the filter with water. After drying under vacuum at 50°C for several hours, 2.28 g of the product are obtained.

d) preparation of 5-bromo-5-(4-methoxyphenyl)barbituric acid

30 To a suspension of 5-(4-methoxyphenyl)barbituric acid (222 mg) in 3 ml of water, cooled to 0-5°C with ice bath, are added 136 µl of 48% hydrobromic acid and 56 µl of bromine, dropwise. After 1 hour at a temperature below 10°C, the solid which separated is collected by filtration and washed on the filter with water. The solid is dried for several hours under vacuum at 50°C, to give 283 mg of the product.

e) preparation of the title compound

A solution of 5-bromo-5-(4-methoxyphenyl)barbituric acid (11.5 g) and N-(2-hydroxyethyl) piperazine (15.755 g) in 260 ml of methanol is refluxed for about 2 hours, then the solid which separated is collected by filtration, redissolved in 100 ml of methanol and heated at reflux for 1 hour. The solid is filtered again and dried at 80°C under vacuum to give 9 g of the product containing 8-9% of methanol. The solid is dissolved in 40 ml of 1 N hydrochloric acid, then the solution is basified with 3.42 g of sodium hydrogencarbonate and cooled at 0-5°C for 4 hours. The product is recovered by filtration and it is dried under vacuum at 80°C for several hours, to give 8.55 g of the pure product, m.p. 247-248°C.

¹H-NMR in d6-DMSO: 2.36 ppm (m, 6H); 2.55 ppm (m, 4H); 3.44 ppm (q, 2H); 3.74 ppm (s, 3H); 4.33 ppm (t, 1H); 6.95 ppm (d, 2H); 7.3 ppm (d, 2H); 11.54 ppm (br s, 2H).

15 **Example 15**

5-[3-(4-methoxyphenyl)propyl]-5-[4-(2-hydroxyethyl)piperazinyl] barbituric acid

a) preparation of 3-(4-methoxyphenyl)propionyl chloride

20 To a suspension of 3-(4-methoxyphenyl)propionic acid (10 g) in 150 ml of toluene are added 8 ml of thionyl chloride and the mixture is heated to 65°C for 4 hours. The solvent is evaporated off under reduced pressure and the residue is redissolved in toluene and concentrated to dryness. Such step is repeated twice. 11 g of the product are obtained as a yellow oil.

25

b) preparation of 5-[3-(4-methoxyphenyl)propionyl]barbituric acid

To a suspension of barbituric acid (6.4 g) in 48 ml of pyridine are added dropwise 11 g of 3-(4-methoxyphenyl)propionyl chloride and the mixture is stirred at room temperature for 18 hours. The reaction mixture is then poured into ice and acidified to pH = 1 by adding 6 N hydrochloric acid. A solid precipitates, which is filtered and resuspended in methanol. The suspension is kept under stirring for 15 minutes, then the solid is recovered by filtration to give 12.2 g of the product. m.p. 248-250°C.

c) preparation of 5-[3-(4-methoxyphenyl)propyl]barbituric acid

To a suspension of 10 g of 5-[3-(4-methoxyphenyl)propionyl]barbituric acid in 100 ml of acetic acid are added portionwise 4.5 g of sodium cyanoborohydride, then the mixture is heated to 60°C. After 1 hour the reaction mixture is cooled to room temperature and poured into ice. After 30 minutes a solid is recovered by filtration, which is dried under vacuum at 50°C to give 8.74 g of the product, m.p. 195-197°C.

d) preparation of 5-bromo-5-[3-(4-methoxyphenyl)propyl]barbituric acid

A mixture of 5-[3-(4-methoxyphenyl)propyl]barbituric acid (2.5 g), N-bromosuccinimide (2 g) and dibenzoyl peroxide (catalytic amount) in 110 ml of carbon tetrachloride is refluxed for about 1 hour, then the solid which separated is filtered. The solid is redissolved in ethyl acetate and filtered through a silica gel cake in order to eliminate the succinimide residue. The organic phase is then concentrated to dryness and the residue is crystallized from diethylether/carbon tetrachloride mixture. A pale yellow solid separates which is filtered and dried under vacuum at 60°C to give 2.8 g of the product, m.p. 113-114°C.

e) preparation of the title compound

A mixture of 5-bromo-5-[3-(4-methoxyphenyl)propyl]barbituric acid (710 mg) and N-(2-hydroxyethyl)piperazine (281 mg) in 25 ml of ethanol is refluxed for 4 hours. The solvent is evaporated under reduced pressure and the residue is partitioned between 1 N hydrochloric acid and ethyl acetate. The aqueous phase is basified to pH = 6-7 and extracted with ethyl acetate. The organic phase is concentrated to dryness and the residue is crystallized from ethyl acetate to give 30 mg of the product.

¹H-NMR in d₆-DMSO: 1.32 ppm (m, 2H); 1.86 ppm (m, 2H); 2.33 ppm (m, 6H); 2.45 ppm (m, 2H); 2.53 ppm (m, 4H); 3.43 ppm (q, 2H); 3.7 ppm (s, 3H); 4.35 ppm (t, 1H); 6.8 ppm (d, 2H); 7.04 ppm (d, 2H); 11.53 ppm (br s, 2H).

Example 16

5-phenyl-5-[4-(2-hydroxyethylidene)piperidinyl]barbituric acid

a) preparation of 4-(ethoxycarbonylmethylidene)piperidine

To a suspension of sodium hydride (2.6 g) in 30 ml of tetrahydrofuran, cooled to 0°C and kept under nitrogen atmosphere, 13 ml of triethylphosphonoacetate, dissolved in 10 ml of tetrahydrofuran, are added dropwise. The temperature is then brought to room

temperature and the stirring is continued for 30 minutes. The mixture is again cooled to 0°C and it is added dropwise with a solution obtained by adding portionwise to a solution of 4-piperidone monohydrate hydrochloride (10 g) in THF 2.6 g of sodium hydride, filtered to eliminate the sodium chloride which formed. At the end of the addition, the temperature is brought to room temperature and the stirring is continued for 20 hours. The solvent is then evaporated under reduced pressure and the residue is redissolved in ethyl acetate and washed with 1 N hydrochloric acid. The aqueous phase is extracted with ethyl acetate and chloroform, then it is basified to pH = 9-10 by adding 20% sodium hydroxide and it is extracted with chloroform. The aqueous phase is then salted and extracted again with chloroform three times. The pooled extracts are dried over sodium sulfate and evaporated to give 7.1 g of the product as a yellow oil.

b) preparation of 4-(hydroxyethylidene)piperidine

A solution of 15 ml of DIBAL (1.5 M solution in toluene) in 20 ml of toluene is added dropwise with 0.976 g of 4-(ethoxycarbonylmethylidene)piperidine, dissolved in few milliliter of toluene. The reaction mixture is stirred at room temperature for 2 hours, then it is cooled to 0-5°C and added dropwise with methanol, until the gaz development is seen. The mixture is concentrated to a little volume and diethyl ether is added: a white solid separates, which is filtered off. The organic phase is concentrated to dryness, redissolved in diethyl ether and again filtered. The clear solution is concentrated to dryness to give 500 mg of the product.

c) preparation of the title compound

A mixture of 5-bromo-5-phenylbarbituric acid (2.45 g), 4-(hydroxyethylidene)piperidine (1.053 g) and triethylamine (1.15 ml) in 50 ml of ethanol is refluxed for 2 hours. The solvent is evaporated under reduced pressure and the residue is purified by silica gel chromatography (40 g; eluent: ethyl acetate/petroleum ether 8:2), to give 450 mg of the product.

¹H-NMR in d6-DMSO: 2.13 ppm (m, 4H); 2.55 ppm (m, 4H); 3.89 ppm (d, 2H); 4.46 ppm (br s, 1H); 5.24 ppm (t, 1H); 7.42 ppm (m, 5H); 11.6 ppm (br s, 2H).

50 mg of 5-phenyl-5-[4-(2-hydroxyethyl)-1,2,5,6-tetrahydropyridinyl]barbituric acid as a side product are also recovered.

¹H-NMR in d6-DMSO: 1.96 ppm (m, 2H); 2.09 ppm (t, 2H); 2.64 ppm (t, 2H); 3.00 ppm (m, 2H); 3.47 ppm (q, 2H); 4.43 ppm (t, 1H); 5.3 ppm (m, 1H); 7.4 ppm (s, 5H); 11.63 ppm (br s, 2H).

Example 175-phenyl-5-[N-(2-hydroxyethyl)piperazinyl]-2-thiobarbituric acid

a) preparation of diethyl 2-bromo-2-phenylmalonate

- 5 To a solution of diethyl 2-phenylmalonate (15 ml) in 200 ml of tetrahydrofuran, kept at 0°C and under nitrogen atmosphere, 3.475 g of sodium hydride are added and the mixture is kept 30 minutes under stirring at 0°C, then it is brought to room temperature. After cooling again to 0°C, the reaction mixture is added with 14.3 g of N-bromosuccinimide. After about 15 minutes, the white solid which separated is filtered off
10 and the filtrate is concentrated to dryness to give a residue which is redissolved in chloroform and dried over sodium sulfate. The solvent is evaporated under reduced pressure to give 15.66 g of the product.

b) preparation of diethyl 2-phenyl-2-[4-(2-hydroxyethyl)piperazinyl]malonate

- 15 A solution of diethyl 2-bromo-2-phenylmalonate (16.8 g) in 150 ml of dimethylsulfoxide is heated to 90-100°C, then N-(2-hydroxyethyl)piperazine (27.9 g) is added and the reaction mixture is heated for additional 4 hours. The mixture is poured into water and extracted with ethyl acetate three times. The pooled organic extracts are washed with 1 N hydrochloric acid. The aqueous phase is basified with 1 N sodium hydroxide to pH =
20 8-9 and it is extracted twice with ethyl acetate. The organic extracts are collected and are washed with a saturated aqueous solution of sodium chloride and dried over sodium sulfate. After removal of the solvent under reduced pressure, the residue is crystallized from diethylether/petroleum ether 1:1 to give 6.5 g of the product, m.p. 63-64°C.

c) preparation of the title compound

- 25 To a solution of sodium (27 mg) in 3 ml of ethanol are added 218 mg of diethyl 2-phenyl-2-[4-(2-hydroxyethyl)piperazinyl]malonate and 288 mg of thiourea, then the mixture is refluxed for about 13 hours. The reaction mixture is cooled to room temperature and 140 µl of acetic acid are added, then the solvent is evaporated under
30 reduced pressure. The residue is redissolved in a ethyl acetate/methanol 9:1 mixture. The solid which separates is filtered off and the filtrate is concentrated to dryness and purified by silica gel chromatography (eluent: from ethyl acetate to ethyl acetate/methanol 9:1), to give, after crystallization from ethyl acetate, 30 mg of the product, m.p. >250°C.

- 35 ¹H-NMR in d6-DMSO: 2.4 ppm (m, 6H); 2.59 ppm (m, 4H); 3.46 ppm (q, 2H); 4.4 ppm (t, 1H); 7.4 ppm (m, 5H); 12.5 ppm (br s, 2H).

Example 18**5-phenyl-5-[N-(2-hydroxyethyl)piperazinyl]-2-azobarbituric acid**

To a solution of sodium (70 mg) in 5 ml of ethanol are added 218 mg of diethyl 2-phenyl-2-[4-(2-hydroxyethyl)piperazinyl]malonate (example 4 - step b) and 172 mg
5 guanidine hydrochloride and the mixture is refluxed for 8 hours. Further 57 mg of guanidine hydrochloride are added and the mixture is refluxed for additional 6 hours. The temperature is brought to room temperature and acetic acid is added until neutralization occurs, then the solid which is formed is filtered off. The filtrate is concentrated to
10 dryness and redissolved in ethanol, from which by adding of ethyl acetate a solid separates. After 1 hour at -4°C the white solid is recovered by filtration and it is recrystallized from methanol (2 ml), to give, after drying under vacuum at 90°C for 4 hours, 78 mg of the product, m.p. >250°C.

15 ¹H-NMR in d6-DMSO: 2.33 ppm (m, 6H); 2.54 ppm (m, 4H); 3.41 ppm (t, 2H); 4.33 ppm (br s, 1H); 7.00 ppm (br s, 1H); 7.33 ppm (m, 5H); 7.5 ppm (br s, 1H); 11.4 ppm (br s, 1H).

Example 19**5-benzyl-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid****a) preparation of 5-benzylidenebarbituric**

A suspension of 5 g of barbituric acid in 50 ml of water is heated until a complete dissolution occurs, then it is added with 4.3 ml of benzaldehyde. The mixture is refluxed for 1 hour, then the solid which separated is filtered, washed several times with water
25 and dried under vacuum at 100°C, to give 8.17 g of the product, m.p. >258°C.

b) preparation of 5-benzylbarbituric acid

To a suspension of 5-benzylidenebarbituric acid (4 g) in 200 ml of methanol are added portionwise 1.4 g of sodium borohydride. After 10 minutes from the end of the addition,
30 100 ml of water are added and the mixture is acidified with 1 N hydrochloric acid to pH = 2. The solvent is evaporated off and the aqueous phase is extracted with ethyl acetate. The pooled extracts are dried over sodium sulfate and concentrated to dryness. 3.6 g of the product crystallize, m.p. 207-209°C.

35 c) preparation of 5-bromo-5-benzylbarbituric acid

To a suspension of 5-benzylbarbituric acid (1.7 g) in 15 ml of water, cooled to 0-5°C, 1 ml of 48% hydrobromic acid are added, followed by the addition dropwise of 0.437 ml

of bromine into the reaction mixture. After 1 hour under stirring at a temperature below 10°C, the solid which formed is separated by filtration and washed with water. 2.17 g of the product are obtained, m.p. 164-166°C.

5 d) preparation of the title compound

A solution of 5-bromo-5-benzylbarbituric acid (2.15 g) and N-(2-hydroxyethyl)piperazine in 50 ml of ethanol is refluxed for 4 hours, then it is cooled to room temperature and added with 4 ml of triethylamine. The solvent is evaporated off and the white residue is redissolved in a ethyl acetate/methanol 3:1 mixture. An orange
10 solid crystallizes, which is recovered by filtration. After recrystallization from ethanol 0.62 g of the product are obtained, m.p. 243-246°C.

¹H-NMR in d₆-DMSO: 2.43 ppm (t, 2H); 2.58 ppm (m, 4H); 3.03 ppm (m, 4H); 3.34 ppm (s, 2H); 3.49 ppm (q, 2H); 4.5 ppm (t, 1H); 7.13 ppm (m, 5H); 8.8 ppm (br s, 2H).

15 **Example 20**

5-[N-(2-hydroxyethyl)piperazinyl]-5-(4-hydroxyphenyl)barbituric acid

a) preparation of 5-(4-hydroxyphenyl)barbituric acid

To a suspension of 5-(4-methoxyphenyl)barbituric acid (222 mg) in 5 ml of methylene
20 chloride, kept at -5/-10°C and under nitrogen atmosphere, is dropped a solution of boron tribromide (473 µl) in 2 ml of methylene chloride. The stirring is continued for additional 2 hours at -5°C, then the temperature is brought to room temperature and stirring is continued for further 20 hours. The reaction mixture is again cooled to 0°C with an ice bath and it is basified to pH = 9-10 by adding dropwise 5% sodium hydroxide. The
25 aqueous phase is separated, filtered through a celite plug, cooled with ice bath and acidified to pH = 1 with 37% hydrochloric acid. A white solid separates which after 1 hour is separated by filtration and dried under vacuum at 60°C to give 215 mg of the product.

30 b) preparation of 5-[4-(tertbutyldimethylsilyloxy)phenyl]barbituric acid

To a solution of 5-(4-hydroxyphenyl)barbituric acid (1.9 g) and tertbutyl dimethylsilyl chloride (4.68 g) in 20 ml of anhydrous dimethylformamide are added 4.4 g of imidazole and the mixture is heated to 55°C for 5 hours. The temperature is then brought to room temperature and the reaction mixture is poured into 1 N hydrochloric acid and extracted
35 twice with ethyl acetate. The pooled organic extracts are washed with water and dried over sodium sulfate. By concentration of the solution a white solid separates, which is kept at 0°C overnight, then it is filtered to give 2.185 g of the product.

c) preparation of 5-bromo-5-[(4-tertbutyldimethylsilyloxy)phenyl]barbituric acid
To a suspension of 5-[4-(tertbutyldimethylsilyloxy)phenyl]barbituric acid (330 mg) and dibenzoyl peroxide (catalytic amount) in 10 ml of carbon tetrachloride are added 210 mg of N-bromosuccinimide. The mixture is stirred at room temperature for 1 hour, then the solvent is evaporated off and the residue is purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 8:2), to give 260 mg of the product.

d) preparation of 5-[N-(2-hydroxyethyl)piperazinyl]-5-[(4-tertbutyldimethylsilyloxy)phenyl]barbituric acid
A solution of 5-bromo-5-[(4-tertbutyldimethylsilyloxy)phenyl]barbituric acid (260 mg) and N-(2-hydroxyethyl)piperazine (98 mg) in 5 ml of ethanol is refluxed for 1 hour, then it is brought to room temperature and added with 0.3 ml of triethylamine. The solvent is evaporated off and the residue is purified by silica gel chromatography (25 g; eluent: ethyl acetate/methanol 3:1), to give, after crystallization from ethyl acetate, 170 mg of the product, m.p. 220-221°C.

e) preparation of the title compound
A mixture of 5-[N-(2-hydroxyethyl)piperazinyl]-5-[(4-tertbutyldimethylsilyloxy)phenyl]barbituric acid (148 mg), tetrabutylammonium fluoride (1.1 M in THF; 0.6 ml) and acetic acid (290 µl) in 10 ml of tetrahydrofuran, kept at 0°C, is stirred for 2 hours 30 minutes, then the solvent is evaporated off and the residue is purified by silica gel chromatography (12 g; eluent: ethyl acetate/methanol 3:1), to give, after crystallization from ethyl acetate and recrystallization from ethyl acetate/methanol mixture, 40 mg of the product, m.p. >25°C.
¹H-NMR in d6-DMSO: 2.37 ppm (m, 6H); 2.55 ppm (m, 4H); 3.45 ppm (q, 2H); 4.35 ppm (t, 1H); 6.76 ppm (d, 2H); 7.17 ppm (d, 2H); 9.72 ppm (s, 1H); 11.47 ppm (br s, 2H).

Example 21

5-[N-(2-hydroxyethyl)piperazinyl]-5-(3-hydroxyphenyl)barbituric acid

a) preparation of ethyl 3-hydroxyphenylacetate
A suspension of 3-hydroxyphenylacetic acid (5.4 g) and para-toluensulfonic acid (650 mg) in 80 ml of ethanol is refluxed for 4 hours, then the solvent is evaporated off and the residue is dissolved in ethyl acetate and washed twice with a saturated aqueous solution of sodium hydrogencarbonate. The organic phase is dried over sodium sulfate and the solvent is evaporated off to give 6.08 g of the product as a yellow oil.

b) preparation of ethyl 3-(tertbutyldimethylsilyloxy)phenylacetate

To a solution of ethyl 3-hydroxyphenylacetate (6 g) and tertbutyldimethylsilyl chloride (6 g) in 80 ml of anhydrous dimethylformamide are added 5.66 g of imidazole and the mixture is stirred at room temperature for 1 hour 30 minutes. The reaction mixture is then poured into water and extracted twice with ethyl acetate. The pooled organic extracts are dried over sodium sulfate and concentrated to dryness to give 10 g of the product as a yellow oil.

c) preparation of diethyl 3-(tertbutyldimethylsilyloxy)phenylmalonate

To a solution of ethyl 3-(tertbutyldimethylsilyloxy)phenylacetate (10 g) in 25 ml of diethylcarbonate are added portionwise 0.86 g of sodium and the mixture is refluxed for 2 hours. The solvent is evaporated off and the residue is poured into water (90 ml). The pH is adjusted to pH = 6 with acetic acid and the mixture is extracted with diethyl ether. The organic phase is dried over sodium sulfate and concentrated to dryness to give 10 g of an orange oil which is purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 95:5), to give 2.45 of the product.

d) preparation of 5-[3-(tertbutyldimethylsilyloxy)phenyl]barbituric acid

To a solution of diethyl 3-(tertbutyldimethylsilyloxy)phenylmalonate (1.5 g) in 15 ml of ethanol are added 0.445 g of sodium ethoxide and 0.295 g of urea and the mixture is refluxed for 3 hours. The reaction mixture is cooled to room temperature and the solid formed is filtered. The solid is redissolved in water, the pH is adjusted to pH = 1-2 with 6 N hydrochloric acid and the solid which precipitates is recovered by filtration. The filtrate is concentrated to eliminate the ethanol, then the solution is basified and extracted with ethyl acetate. The organic phase is concentrated to dryness to give 250 mg of residue which is pooled with the solid previously filtered (350 mg). The residue so obtained contains a mixture of the product along with the de-silylated derivative.

Such a residue (550 mg) is dissolved in 5 ml of anhydrous dimethylformamide and 790 mg of tertbutyldimethylsilyl chloride and 745 mg of imidazole are successively added. The mixture is heated to 55°C for 5 hours. Further 75 mg of imidazole and 79 mg of tertbutyldimethylsilyl chloride are added and the heating is continued for an additional hour. The reaction mixture is then poured into 1 N hydrochloric acid and extracted three times with ethyl acetate. The pooled organic extracts are washed with water and dried over sodium sulfate. The solution is concentrated and a white solid precipitates. 710 mg of the product are recovered by filtration.

- e) preparation of 5-[3-(tertbutyldimethylsilyloxy)phenyl]-5-bromobarbituric acid
A mixture of 5-[3-(tertbutyldimethylsilyloxy)phenyl]barbituric acid (680 mg), N-bromosuccinimide (432 mg) and dibenzoyl peroxide (catalytic amount) in 10 ml of carbon tetrachloride are stirred at room temperature for 1 hour. The solvent is
5 evaporated off and the residue is purified by silica gel chromatography (eluent: ethyl acetate/hexane 7:3) to give 550 mg of the product, m.p. 170-172°C.
- f) preparation of 5-[N-(2-hydroxyethyl)piperazinyl]-5-[3-(tertbutyldimethylsilyloxy)phenyl]barbituric acid
10 A solution of 5-[3-(tertbutyldimethylsilyloxy)phenyl]-5-bromobarbituric acid (444 mg) and N-(2-hydroxyethyl)piperazine (420 mg) in 10 ml of methanol is stirred at room temperature for 5 hours, then the solvent is evaporated off and the residue is purified by silica gel chromatography (13 g; eluent: ethyl acetate/methanol 3:1), to give 70 mg of the product.
- 15 g) preparation of the title compound
To a solution of 5-[N-(2-hydroxyethyl)piperazinyl]-5-[3-(tertbutyldimethylsilyloxy)phenyl]barbituric acid (170 mg) in 12 ml of tetrahydrofuran, kept at 0°C and under nitrogen atmosphere, are added 333 µl of acetic acid and 0.69 ml
20 of tetrabutylammonium fluoride. The mixture is stirred for 3 hours then the solvent is evaporated off and the residue is purified by silica gel chromatography (15 g; eluent: ethyl acetate/methanol 4:1), to give, after crystallization from methanol, 35 mg of the product, m.p. 219-221°C.
¹H-NMR in d6-DMSO: 2.37 ppm (m, 6H); 2.59 ppm (m, 4H); 3.45 ppm (q, 2H); 4.35 ppm (t, 1H); 6.74 ppm (m, 2H); 6.92 ppm (t, 1H); 7.18 ppm (t, 1H); 9.62 ppm (s, 1H);
25 11.54 ppm (br s, 2H).

Example 22

5-[N-(2-hydroxyethyl)piperazinyl]-5-(4-methylphenyl)barbituric acid

- 30 a) preparation of 5-(4-methylphenyl)barbituric acid
To a solution of sodium (184 mg) in 12 ml of ethanol are added 0.95 ml of diethyl 2-(4-methylphenyl)malonate and 360 mg of urea, then the mixture is refluxed for 3 hours. A white solid separates, which is filtered and redissolved in 4 ml of water. The solution is
35 acidified to pH = 1-2 by adding 6 N hydrochloric acid. A white solid separates, which is collected by filtration, washed with 15 ml of water and dried under vacuum. 619 mg of the product are obtained, m.p. 271°C.

b) preparation of 5-bromo-5-(4-methylphenyl)barbituric acid

To a suspension of 5-(4-methylphenyl)barbituric acid (218 mg) in 2 ml of water, kept at 10°C under stirring, 136 µl of 48% hydrobromic acid are added, then 56 µl of bromine are dropped and the stirring is continued for 3 hours. The precipitate which formed is recovered by filtration and washed with water, then it is dried under vacuum to give 270 mg of the product, m.p. 210-213°C.

c) preparation of the title compound

A solution of 5-bromo-5-(4-methylphenyl)barbituric acid (3.1 g) and of N-(2-hydroxyethyl) piperazine (1.53 g) in 60 ml of ethanol is refluxed for 3 hours. The solvent is evaporated off and the residue is dissolved in 1 N hydrochloric acid and washed twice with ethyl acetate. The aqueous phase is basified with 1 N sodium hydroxide and extracted with ethyl acetate. The organic extracts are concentrated to dryness and the residue is purified by silica gel chromatography (100 g; eluent: ethyl acetate/methanol 3:1), to give, after evaporation of the solvent, 1.97 g of the product as hydrobromide.

The free base is obtained by treating an ethyl acetate suspension (200 ml) of the salt with 50 ml of a saturated aqueous solution of sodium hydrogencarbonate and by extraction of the aqueous phase with ethyl acetate. By concentrating to dryness the pooled organic extracts 1.18 g of the product are obtained.

¹H-NMR in d₆-DMSO: 2.3 ppm (s, 3H); 2.35 ppm (m, 6H); 2.57 ppm (m, 4H); 3.45 ppm (q, 2H); 4.35 ppm (t, 1H); 7.19 ppm (d, 2H); 7.28 ppm (d, 2H); 11.55 ppm (br s, 2H).

Example 23

5-octyl-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid

a) preparation of diethyl 2-octylmalonate

To a solution of 2.63 g of sodium in 100 ml of ethanol is added dropwise a solution of 19.1 ml of diethylmalonate in 10 ml of ethanol. The mixture is successively added with 20.4 ml of 1-bromooctane dissolved in 10 ml of ethanol, then the mixture is refluxed for 6 hours. The reaction mixture is concentrated to a little volume and the residue is partitioned between a saturated aqueous solution of sodium hydrogenphosphate (200 ml) and ethyl acetate (200 ml). The organic phase is washed with 75 ml of water and 75 ml of saturated aqueous solution of sodium chloride, dried over sodium sulfate and concentrated to dryness, to give 31.8 g of the product as an oil.

¹H-NMR in CDCl₃: 0.80-0.95 ppm (m, 3H); 1.15-1.40 ppm (m, 18H); 1.88 ppm (q, 2H); 3.33 ppm (t, 1H); 4.19 ppm (q, 4H).

b) preparation of 5-octylbarbituric acid

5 To a solution of sodium (5.32 g) in 400 ml of anhydrous ethanol is added a solution of diethyl 2-octylmalonate (31.5 g) in 50 ml of ethanol and successively 10.27 g of urea, then the mixture is refluxed for 2 hours 30 minutes. The mixture is rapidly cooled to room temperature and the solid which was formed is recovered by filtration and washed with diethyl ether. The solid is then dissolved in 200 ml of water and acidified with 6 N
10 hydrochloric acid until pH 1.5-2 is reached. A solid separates. The mixture is added with 200 ml of ethyl acetate and it is stirred for 2 hours, then it is added with additional 800 ml of warm ethyl acetate. The organic phase is separated and the aqueous phase is washed with 200 ml of ethyl acetate. The pooled organic phases are washed with 250 ml of saturated aqueous solution of sodium chloride, dried over sodium sulfate and
15 concentrated to dryness. 21.03 g of the product are obtained.

¹H-NMR in d₆-DMSO: 0.77-0.80 ppm (m, 3H); 1.23 ppm (s, 12H); 1.80-1.95 ppm (m, 2H); 3.52 ppm (t, 1H); 11.15 ppm (s, 2H).

c) preparation of 5-bromo-5-octylbarbituric acid

20 To a suspension of 5-octylbarbituric acid (20 g) in 120 ml of water, cooled at 0-5°C, are added 12 ml of 48% hydrobromic acid and successively are dropped 4.72 ml of bromine. After 2 hours under stirring, the white solid which separated is recovered by filtration, washed with water and partitioned between 200 ml of diethyl ether and 100 ml of water. The aqueous phase is extracted with additional 50 ml of diethyl ether. The pooled
25 organic phases are washed with 75 ml of saturated aqueous solution of sodium chloride, dried over sodium sulfate and concentrated to dryness. 25.8 g of the product as white solid are obtained.

¹H-NMR in d₆-DMSO: 0.78-0.90 ppm (m, 3H); 1.10-1.38 ppm (m, 12H); 2.20-2.34 ppm (m, 2H); 11.80 ppm (s, 2H).

30

d) preparation of the title compound

To a solution of 5-bromo-5-octylbarbituric acid (23.52 g) in 70 ml of dimethylsulfoxide, kept under nitrogen atmosphere and at a temperature of 5-10°C, is dropped N-(2-hydroxyethyl)piperazine (36.2 ml), then the mixture is stirred at room temperature for 2
35 hours 30 minutes. The reaction mixture is poured into water (1 l) under stirring and cooling with an ice bath. The white solid which separates is recovered by filtration.

washed with water and dried under vacuum at 40°C, to give, after crystallization from ethanol (140 ml) 10.91 g of the product as a white solid, m.p. 183-184°C.

¹H-NMR in d₆-DMSO: 0.75-0.88 ppm (m, 3H); 0.90-1.10 ppm (m, 2H); 1.12-1.30 ppm (m, 10H); 1.75-1.90 ppm (m, 2H); 2.23-2.40 ppm (m, 6H); 2.45-2.60 ppm (m, 4H); 3.45 ppm (br t, 2H); 4.35 ppm (br s, 1H); 11.55 ppm (s, 2H).

Example 24

5-naphtyl-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid

10

a) preparation of ethyl 2-naphtylacetate

To a solution of 2-naphtylacetic acid (5 g) in 50 ml of ethanol are added 0.5 g of para-toluensulfonic acid, then the reaction mixture is refluxed for about 4 hours. The solvent is evaporated off and the residue is dissolved in diethyl ether, washed twice with a saturated aqueous solution of sodium hydrogencarbonate and once with brine, then the pooled organic extracts are dried over sodium sulfate and concentrated to dryness. 5.64 g of the product as a yellow oil are obtained.

b) preparation of diethyl 2-naphtylmalonate

To a solution of ethyl 2-naphtylacetate (2 g) in 23.3 ml of diethylcarbonate, kept under stirring and at room temperature, are added portionwise 0.232 g of sodium. The reaction mixture is refluxed for 2 hours 30 minutes, then it is concentrated in order to eliminate the not reacted diethylcarbonate and it is added with 20 ml of cold water. The resulting mixture is acidified with acetic acid until weak acidity is reached, then it is extracted three times with diethyl ether. The pooled organic extracts are dried over sodium sulfate and the solvent is evaporated off, to give, after recrystallization from diethyl ether (19 ml), 1.015 g of the product as a white solid.

c) preparation of 5-naphtylbarbituric acid

A solution of sodium (0.32 g) in 30 ml of anhydrous ethanol is added with diethyl 2-naphtylmalonate (2 g) and successively with urea (0.63 g). The mixture is refluxed for 2 hours, then the solid which separated is recovered by filtration, then it is dissolved in 7 ml of water and acidified to pH = 1 with 6 N hydrochloric acid. A white solid precipitates which, after 30 minutes under stirring, is filtered and washed with water. The solid is dried overnight under vacuum at 40°C, to give 0.96 g of the product.

d) preparation of 5-bromo-5-naphtylbarbituric acid

A suspension of 5-naphtylbarbituric acid (0.2 g) in 1.5 ml of 95% ethanol, cooled at 0°C and kept under stirring, is added dropwise with 48% hydrobromic acid (0.5 ml) and successively with 4.4 µl of bromine. After 4 hours under stirring at room temperature the solid is filtered and washed with water, then it is dried under vacuum at 40°C overnight. 0.25 g of the product are obtained.

e) preparation of the title compound

To a suspension of 5-bromo-5-naphtylbarbituric acid (0.24 g) in 3.5 ml of ethanol is added a solution of N-(2-hydroxyethyl)piperazine (0.112 g) in 1.5 ml of ethanol. The reaction mixture is refluxed for 5 hours, then it is cooled to room temperature and the solid which separates is filtered off. The filtrate is added with 100 µl of triethylamine, then the solvent is evaporated off to give 0.364 g of a solid, which is recrystallized from a mixture of methanol (4.5 ml) and ethyl acetate (10 ml). The obtained solid (70 mg) is washed under stirring with an ethyl acetate/water mixture for 2 hours and dried under vacuum at 40°C for 8 hours, to give 60 mg of the product.

¹H-NMR in d6-DMSO: 2.3-2.5 ppm (m, 6H); 2.6 ppm (m, 4H); 3.45 ppm (m, 2H); 4.35 ppm (t, 1H); 7.4-8.1 ppm (m, 7H); 11.65 ppm (s, 2H).

20 **Example 25**5-(4'-biphenyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid

a) preparation of ethyl (4'-biphenyl)acetate

A suspension of (4'-biphenyl)acetic acid (6.4 g) in 60 ml of ethanol is added with 1.1 g of para-toluensulfonic acid, then the reaction mixture is refluxed for 4 hours 30 minutes. The solvent is evaporated off, the residue is dissolved in diethyl ether and the resulting organic phase is washed three times with a saturated aqueous solution of sodium hydrogencarbonate and once with brine. The organic phase is then dried over sodium sulfate and the solvent is evaporated off to give 7.1 g of the product as a yellow oil.

30

b) preparation of diethyl (4'-biphenyl)malonate

A solution of ethyl (4'-biphenyl)acetate (7.1 g) in 60 ml of diethylcarbonate, kept under nitrogen atmosphere, is added portionwise with sodium (0.734 g), then it is heated at 120°C for 3 hours. The solvent is evaporated off and the residue is dissolved in 65 ml of cold water and acidified with acetic acid until pH = 5-6 is reached. The aqueous phase is then extracted three times with diethyl ether and the pooled organic extracts are dried over sodium sulfate and concentrated to dryness. The residue is purified by silica gel

35

chromatography (eluent: petroleum ether/diethyl ether 9.4:0.6) to give 7.05 g of the product, m.p. 51-53°C.

c) preparation of 5-(4'-biphenyl)barbituric acid

- 5 A solution of sodium (0.322 g) in 40 ml of anhydrous ethanol is added with diethyl (4'-biphenyl)malonate (2.2 g) and successively with urea (0.63 g). The reaction mixture is refluxed for 3 hours 30 minutes, then it is cooled to room temperature and the solid is recovered by filtration. The obtained solid is redissolved in 40 ml of warm water and the resulting aqueous phase is acidified to pH = 1 with 6 N hydrochloric acid. The solid
10 which separates is kept 15 minutes under stirring, then it is filtered and dried under vacuum at 60°C. 1.1 g of the product are obtained, m.p. >240°C.

d) preparation of 5-bromo-5-(4'-biphenyl)barbituric acid

- A suspension of 5-(4'-biphenyl)barbituric acid (0.28 g) in 1.4 ml of water, cooled at 0°C
15 and kept under stirring, is added dropwise with 0.14 ml of 48% hydrobromic acid and successively with 55.5 µl of bromine. The temperature is then brought to room temperature and the stirring is continued for 1 hour. The suspended solid is recovered by filtration, washed with water and dried under vacuum at 60°C for 2 hours, to give 0.336 of the product, m.p. 203-205°C.

20

e) preparation of the title compound

- To a suspension of 5-bromo-5-(4'-biphenyl)barbituric acid (0.323 g) in 4.4 ml of ethanol 0.14 g of N-(2-hydroxyethyl)piperazine are added and the reaction mixture is refluxed for 2 hours. The suspended solid is filtered off and the resulting clear solution is treated
25 with 125 µl of triethylamine, then the solvent is evaporated off. The residue is redissolved in 2 ml of ethanol, from which crystallizes a solid which is stirred for 30 minutes, then it is filtered. The residue is recrystallized from ethanol to give 100 mg of the pure product, m.p. 225-226°C.

- ¹H-NMR in d₆-DMSO: 2.3-2.5 ppm (m, 6H); 2.65 ppm (m, 4H); 3.45 ppm (m, 2H); 4.4
30 ppm (s, 1H); 7.3-7.8 ppm (m, 9H); 11.6 ppm (s, 2H).

Example 26

5-(4'-biphenyl)-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid

- 35 A solution of 5-bromo-5-(4'-biphenyl)barbituric acid (0.359 g; example 25, step d) in 9 ml of methanol is added with 0.622 g of N-(4-nitrophenyl)piperazine and the mixture is refluxed for about 2 hours. The solvent is evaporated off and the residue is partitioned

between water and ethyl acetate. The organic phase is separated, washed with brine and dried over sodium sulfate. The solvent is then evaporated under reduced pressure to give 0.74 g of a residue which is purified by silica gel chromatography (eluent: methylene chloride/acetone 9:1) to give 400 mg of the product, m.p. 181°C.

5

¹H-NMR in d₆-DMSO: 2.8 ppm (m, 4H); 3.5 ppm (m, 4H); 7.00 ppm (d, 2H); 7.3-7.85 ppm (m, 9H); 8.05 ppm (d, 2H); 11.7 ppm (s, 2H).

Example 27

10 5-(4'-phenoxyphenyl)-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid

a) preparation of N-[(4'-phenoxybenzyl)thiocarbonyl]morpholine

A mixture of (4'-phenoxyphenyl)methylketone (19.1 g), morpholine (20 ml) and sulphur (4.32 g) is refluxed for 24 hours, then it is extracted with diethyl ether. The organic
15 phase is concentrated to dryness to give, after crystallization from a petroleum ether/ethyl acetate mixture 8:2 (600 ml), 12.2 g of the product, m.p. 75-77°C.

b) preparation of (4'-phenoxyphenyl)acetic acid

A suspension of N-[(4'-phenoxybenzyl)thiocarbonyl]morpholine (1.725 g) in 87 ml of
20 10% potassium hydroxide is refluxed for 8 hours 30 minutes, then the reaction mixture is brought to room temperature and acidified with 1N hydrochloric acid. A white solid separates, which is stirred for 30 minutes and filtered. The solid is washed with water and dried under vacuum, to give 1.095 g of the product, m.p. 70-72°C.

25 c) preparation of ethyl (4'-phenoxyphenyl)acetate

To a suspension of (4'-phenoxyphenyl)acetic acid (0.456 g) in 4 ml of ethanol is added para-toluensulfonic acid (0.076 g) and the resulting mixture is refluxed for 2 hours. The solvent is evaporated off, the residue is dissolved in diethyl ether and the organic phase is washed with saturated aqueous solution of sodium hydrogencarbonate and then with
30 brine. The organic phase is dried over sodium sulfate and concentrated to dryness to give 0.458 g of the product as a brown oil.

d) preparation of 5-(4'-phenoxyphenyl)barbituric acid

A solution of sodium ethoxide (0.27 g) in 3 ml of anhydrous ethanol is added with 0.657
35 g of ethyl (4'-phenoxyphenyl)acetate dissolved in 5 ml of ethanol, then with urea (0.18 g). The reaction mixture is refluxed for 2 hours 30 minutes, then it is cooled to room temperature and the suspended solid is filtered. The solid is redissolved in 8 ml of water

and the solution is acidified with 1 N hydrochloric acid. The solid which separates is recovered by filtration to give 0.165 g of the product, m.p. >240°C.

e) preparation of 5-bromo-5-(4'-phenoxyphenyl)barbituric acid

- 5 To a suspension of 5-(4'-phenoxyphenyl)barbituric acid (48 mg) in 0.23 ml of water, cooled at 0°C and under stirring, are added 23 µl of 48% hydrobromic acid and successively 9 µl of bromine. After 2 hours at room temperature additional 9 µl of bromine are added and stirring is continued for 2 hours. The suspended solid is then filtered and washed with water, to give, after drying under vacuum at 60°C, 57 mg of the
10 product, m.p. 125-127°C.

f) preparation of the title compound

- A solution of 5-bromo-5-(4'-phenoxyphenyl)barbituric acid (50 mg) in 0.2 ml of methanol is added dropwise with a solution of N-(2-hydroxyethyl)piperazine (52 mg) in
15 0.6 ml of methanol and the mixture is stirred for 2 hours. The white precipitate is recovered by filtration and dried under vacuum at 60°C overnight. 42.6 mg of the product are obtained, m.p. >240°C.

- ¹H-NMR in d₆-DMSO: 2.2-2.45 ppm (m, 6H); 2.55 ppm (m, 4H); 3.45 ppm (m, 2H);
20 4.4 ppm (t, 1H); 6.9-7.7 ppm (m, 9H); 11.6 ppm (s, 2H).

Example 28

5-decyl-5-[N-(2-hydroxyethyl)piperazinyl]barbituric acid

- 25 a) preparation of diethyl decylmalonate

- A solution of sodium (0.46 g) in 10 of anhydrous ethanol is added with 3.35 ml of diethyl malonate in 3 ml of ethanol and successively with a solution of decylbromide (4.15 ml) in 3 ml of ethanol. The reaction mixture is refluxed for 4 hours, then the precipitate is filtered off and the filtrate is concentrated to dryness. The residue is redissolved in a
30 saturated aqueous solution of sodium hydrogensulfate and it is extracted with ethyl acetate. The organic extract is dried over sodium sulfate and the solvent is evaporated off. The resulting residue is used as such in the successive reaction.

b) preparation of 5-decylbarbituric acid

- 35 To a solution of diethyl decylmalonate of step a) in 40 ml of ethanol are added 2.72 g of sodium ethoxide and then 1.8 g of urea. The reaction mixture is refluxed for 2 hours, then the precipitate is filtered and redissolved in 40 ml of water. The resulting aqueous

solution is acidified with 6 N hydrochloric acid. The solid which separates is recovered by filtration and dried under vacuum at 40°C overnight, to give 2.152 g of the product, m.p. 190°C.

5 c) preparation of 5-bromo-5-decylbarbituric acid

To a suspension of 5-decylbarbituric acid (0.537 g) in 2.9 ml of water are added under stirring at room temperature 0.29 ml of 48% hydrobromic acid. The mixture is cooled to 0°C and 0.113 ml of bromine are dropped. The reaction mixture is stirred at room
10 temperature for 1 hour 30 minutes, then the white precipitate is filtered and it is washed with water. The solid is partitioned between water and diethyl ether, the organic phase is separated, washed with brine and finally dried over sodium sulfate. By evaporation of the solvent under reduced pressure 0.62 g of the product are recovered.

d) preparation of the title compound

15 To a solution of 5-bromo-5-decylbarbituric acid (0.619 g) in 1.3 ml of dimethylsulfoxide, kept under stirring at 0°C, a solution of 0.93 g of N-(2-hydroxyethyl)piperazine in 0.7 ml of dimethylsulfoxide is added dropwise, then the reaction mixture is stirred at room temperature for 1 hour. The mixture is then cooled to 0°C and added with 30 ml of water. A white solid separates, which is kept under stirring for 1 hour, then is filtered and
20 dried under vacuum at 50°C. 0.309 g of the product are obtained, m.p. 181-182°C.

¹H-NMR in d₆-DMSO: 0.85 ppm (t, 3H); 0.9-1.1 ppm (m, 2H); 1.15-1.4 ppm (m, 14H); 1.8-1.9 ppm (m, 2H); 2.2-2.45 ppm (m, 6H); 2.55 ppm (m, 4H); 3.45 ppm (m, 2H); 4.35 ppm (t, 1H); 11.55 ppm (s, 2H).

25

Example 29

5-hexdecyl-5-[N-(2-hydroxyethyl)piperazine]barbituric acid

The title compound was prepared in an analogous manner like the compound of example 28.

30

Example 30

5-eicoxyl-5-[N-(2-hydroxyethyl)piperazine]barbituric acid

The title compound was prepared in an analogous manner like the compound of example 28.

Example 31

5-(4-butoxyphenyl)-5-[4-(2-hydroxyphenyl)piperazinyl]barbituric acid

m.p. 184-185°

H-N.M.R. in d6-DMSO: 0.91 ppm (t, 3H); 1.4 ppm (m, 2H); 1.67 ppm (m, 2H); 2,36
 5 ppm (m, 6H); 2.55 ppm (m, 4H); 3.44 ppm (q, 2H); 3.95 ppm (t, 2H); 4.37 ppm (t, 1H);
 6.95 ppm (d, 2H); 7.28 ppm (d, 2H); 11.5 ppm (br. s, 2H).

The compound is prepared as described in Example 14. The only difference is in the
 preparation of the starting material ethyl 4-butoxyphenyl acetate, which can be prepared
 starting from 4-hydroxyphenylacetic acid by esterification with ethanol (see example 14-
 10 a) and subsequent alkylation of ethyl 4-hydroxyphenyl acetate with butyl bromide
 alkylation of ethyl 4-hydroxyphenyl acetate with butyl bromide, according to known
 methodologies.

Example 32

15 The pathway of production as described in the specification and exemplified in the
 previous examples the following compounds are synthesized. They are characterized by
 mass spectroscopy.

32. Name	MW	exp. mass
xx		
01 N-(2,4,6-Trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	323.3	323
02 3-(3,4-Dimethoxy-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acrylamide	409.4	409
03 3-(3,4,5-Trimethoxy-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acrylamide	439.4	439
04 3-Phenyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-propionamide	351.4	351
05 5-Phenyl-pentanoic acid (2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide	379.4	379
06 2-(4-Nitro-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acetamide	382.3	382
07 3-Benzenesulfonyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-propionamide	415.4	415
08 2-(4-Bromomethyl-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acetamide	430.3	429
09 2-Naphthalen-2-yl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acetamide	387.4	387
10 2-(3-Chloro-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acetamide	371.8	371
11 3-(2-Methoxy-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-propionamide	381.4	381
12 3-(4-Methoxy-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-propionamide	381.4	381
13 2-(3-Bromo-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acetamide	416.2	415

14	3-Phenyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acrylamide	349.3	349
15	4-Bromo-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	402.2	401
16	3-Methyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	337.3	337
17	4-Methylsulfanyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	369.4	369
18	3-Chloro-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	357.8	357
19	4-Chloro-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	357.8	357
20	3,4-Dimethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	351.4	351
21	3,5-Dimethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	351.4	351
22	4-Ethoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	367.4	367
23	4-Cyano-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	348.3	348
24	3-Methoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	353.3	353
25	4-Methoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	353.3	353
26	2-Methyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	337.3	337
27	2,4-Difluoro-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	359.3	359
28	N-(2,4,6-Trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-isonicotinamide	324.3	324
29	Naphthalene-1-carboxylic acid (2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide	373.4	373
30	1-(4-Fluoro-phenyl)-3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-urea	356.3	356
31	3-(4-Methoxy-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acrylamide	379.4	379
32	1-(3-Trifluoromethyl-phenyl)-3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-urea	406.3	406
33	3-(4-Chloro-phenyl)-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-acrylamide	383.8	383
34	1-(2,4-Dichloro-phenyl)-3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-urea	407.2	406
35	1-(3,4-Dichloro-phenyl)-3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-urea	407.2	406
36	1-(Chlor-phenyl)-3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-urea	372.7	372
37	1-(4-Methoxy-phenyl)-3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-urea	368.4	368
38	1-Phenyl-3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-urea	338.3	338
39	Naphthalene-2-carboxylic acid (2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide	373.4	373
40	1H-Indole-5-carboxylic acid (2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide	362.3	362
41	N-(2,4,6-Trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-	366.3	366

	terephthalamide		
42	4-Sulfamoyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	402.4	402
43	4-Methyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	337.3	337
44	4-Ethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	351.4	351
45	4-Methyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzenesulfonamide	373.4	373
46	4-Bromo-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzenesulfonamide	438.3	437
47	2-Trifluoromethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzenesulfonamide	427.4	427
48	5-Phenyl-5-(4-phenyl-piperidin-1-yl)-pyrimidine-2,4,6-trione	363.4	363
49	2,3-Dimethoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	383.4	383
50	2,3-Dimethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	351.4	351
51	4-Hydroxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	339.3	411 silyl.
52	3,4-Dimethoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	383.4	383
53	3-Dimethylamino-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	366.4	366
54	3-tert-Butyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	379.4	379
55	3,4-Dimethoxy-2-nitro-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	428.4	428 + FAB
56	4-Butoxy-3-methoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	425.4	425 + FAB
57	2-Methyl-2,3-dihydro-benzofuran-7-carboxylic acid (2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide	379.4	379 + FAB
58	1H-Indole-4-carboxylic acid (2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide	362.3	362
59	4-Methyl-3-sulfamoyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	416.4	416
60	Acetic acid 6-methyl-2-nitro-3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-ylcarbamoyl)-phenyl ester	440.4	440 + FAB
61	Carbonic acid ethyl ester 2-methoxy-4-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-ylcarbamoyl)-phenyl ester	441.4	441 + FAB
62	2-Bromo-3-nitro-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	447.2	446
63	"4-Chloro-3-sulfamoyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide e"	436.8	436
65	3-tert-Butyl-2-hydroxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	395.4	395
66	4'-Benzyloxy-biphenyl-3-carboxylic acid (2,4,6-trioxo-5-phenyl-hexahydro-pyrimidinein-5-yl)-amide	505.5	505 + FAB
67	3-Cyano-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	348.3	348
68	3-Bromo-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	402.2	401
69	3-Phenoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	415.4	415 + FAB

70	3-Benzoyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	427.4	427
71	3-Trifluoromethyl-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	391.3	391
72	N-(2,4,6-Trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-isophthalamide methyl ester	381.3	381
73	9H-Fluorene-1-carboxylic acid (2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide	411.4	411
74	9-Oxo-9H-fluorene-1-carboxylic acid (2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-amide	425.4	425
75	5-Phenyl-5-(4-phenyl-piperazin-1-yl)-pyrimidine-2,4,6-trione	364.4	364
76	5-Phenyl-5-[4-(2-trifluoromethyl-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione	432.4	432
77	5-[4-(4-Nitro-phenyl)-piperazin-1-yl]-5-phenyl-pyrimidine-2,4,6-trione	409.4	409
78	5-(4-Phenethyl-piperazin-1-yl)-5-phenyl-pyrimidine-2,4,6-trione	392.5	392
79	5-[4-(3-Methoxy-phenyl)-piperazin-1-yl]-5-phenyl-pyrimidine-2,4,6-trione	394.4	394
80	3-Acetylamino-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	380.4	380
81	Acetic acid 3-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-ylcarbamoyl)-phenyl ester	381.3	381
82	3-Ethoxy-N-(2,4,6-trioxo-5-phenyl-hexahydro-pyrimidin-5-yl)-benzamide	367.4	367
83	5-Phenyl-5-(4-pyridin-4-yl-piperazin-1-yl)-pyrimidine-2,4,6-trione	365.4	365
84	5-Phenyl-5-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione	432.4	432
85	5-[4-(4-Methoxy-phenyl)-piperazin-1-yl]-5-phenyl-pyrimidine-2,4,6-trione	394.4	394
86	5-(4-Benzhydryl-piperazin-1-yl)-5-phenyl-pyrimidine-2,4,6-trione	454.5	454 + FAB
87	5-Phenyl-5-[4-(3-phenyl-allyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione	404.5	404 + FAB
88	5-Phenyl-5-(2-pyrrolidin-1-yl-ethylamino)-pyrimidine-2,4,6-trione	316.4	316
89	5-[2-(3H-Imidazol-4-yl)-ethylamino]-5-phenyl-pyrimidine-2,4,6-trione	313.3	313 + FAB

Example 33

- 5 In order to determine the inhibition of MMPs, for example HNC, the catalytic domain (isolation and purification see for example Schnierer, S., Kleine, T., Gote, T., Hillemann, A., Knäuper, V., Tschesche, H., Biochem. Biophys. Res. Commun. (1993) 191, 319-326) is incubated with inhibitors having various concentrations. Subsequently, the initial reaction rate in the conversion of a standard substrate is measured in a manner analogous
- 10 to Grams F. et al., FEBS 335 (1993) 76-80).

The results are evaluated by plotting the reciprocal reaction rate against the concentration of the inhibitor. The inhibition constant (K_i) is obtained as the negative section of the abscissis by the graphical method according to Dixon, M., Biochem. J. (1953) 55, 170-202.

5

The synthetic collagenase substrate is a heptapeptide which is coupled, at the C-terminus, with DNP (dinitrophenol). Said DNP residue quenches by steric hindrance the fluorescence of the adjacent tryptophane of the heptapeptide. After cleavage of a tripeptide which includes the DNP group, the tryptophane fluorescence increases. The proteolytic cleavage of the substrate therefore can be measured by the fluorescence value.

10

a) First method

The assay was performed at 25 °C in a freshly prepared 50 mM Tris buffer (pH 8.0) treated with dithiozone to remove traces of heavy metals. 4 mM CaCl_2 was added and the buffer saturated with argon. Stock solutions of adamalysin II were prepared by centrifugation of the protein from an ammonium sulfate suspension and subsequent dissolution in the assay buffer. Stock solutions of collagenase were diluted with the assay buffer. Enzyme concentrations were determined by uv measurements ($\epsilon_{280} = 2.8 \cdot 10^4 \text{ M}^{-1} \text{ cm}^{-1}$, $\epsilon_{288} = 2.2 \cdot 10^4 \text{ M}^{-1} \text{ cm}^{-1}$) and the stock solutions were stored in the cold. This solution was diluted 1:100 to obtain the final 16 nM assay concentration. The fluorogenic substrate DNP-ProLeu-Gly-LeuTrp-Ala-D-Arg- NH_2 with a K_m of 52 μM was used at a concentration of 21.4 μM ; for the K_i determination a 12.8 μM concentration has also been used. Substrate fluorescence was measured at an excitation and emission wavelength of $\lambda = 320$ and 420 nm, respectively, on a spectrofluorimeter (Perkin Elmer, Model 650-40) equipped with a thermostated cell holder. Substrate hydrolysis was monitored for 10 min. immediately after adding the enzyme. All reactions were performed at least in triplicate. The K_i values-of the inhibitors were calculated from the intersection point of the straight lines obtained by the plots of v_o/v_i vs. [concentration of inhibitor], whereas IC_{50} values were calculated from plots of v_i/v_o [concentration of inhibitor] by non-linear regression with simple robust weighting.

20
25
30

b) Second method

35 Assay buffer:

50 mM Tris/HCl pH 7.6 (Tris= Tris-(hydroxymethyl)-aminomethan)

100 mM NaCl/10 mM CaCl_2 /5 % MeOH (if necessary)

Enzyme: 8 nM catalytic domain (Met80-Gly242) of human neutrophil collagenase

Substrate: 10 microM DNP-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH₂

Total assay volume: 1 ml

5

A solution of the enzyme and inhibitor in assay buffer (25 °C) was prepared. The reaction was started directly by giving the substrate into the solution. The cleavage of the flourogenic substrate was followed by flourescence spectroscopy with an excitation and emission wavelength of 280 and 350 nm, respectively. The IC₅₀ value was calculated as the inhibitor concentration, which is necessary to decrease the velocity of the reaction to the half in comparison to the reaction without inhibitor.

10


Table 1 shows the IC₅₀ values found.

15 **Table 1: IC₅₀ Values of MMP-Inhibitor (MMP-8)**

Compound	IC-50 [nM]
example 32.74	890
preferred no. 120	150
example 25	140
example 23	110
example 20	860
example 32.77	160
preferred no. 118	60
example 28	320
example 26	15

Claims

1. A compound of formula I



in which

X, Y and Z are independently of one another oxygen, sulphur or NH,

R₁ represents a group W-V

W is a valence dash or a straight-chained or branched C₁-C₈ alkyl or a C₂-C₈ alkenyl group which is optionally once or several times substituted,

V is an optionally substituted monocycle or bicycle which can contain one or several heteroatoms. or

W-V is a C₁-C₂₀ alkyl group which can be interrupted by heteroatoms, one or several carbon atoms are optionally substituted,

R₂ and R₃ represent hydrogen or one of the two represents lower alkyl or lower acyl

R₄ and R₅ denote independently of each other for A-D

wherein A represents a dash alkyl, alkenyl, acyl, alkylsulfonyl, sulfonyl, alkylaminocarbonyl, aminocarbonyl, alkoxycarbonyl, oxy-carbonyl, alkylaminothiocarbonyl, aminothio-carbonyl which is optionally once or several times substituted,

D represents a hydrogen, monocycle or bicycle, the monocycle or bicycle is optionally once or several times interrupted by heteroatoms and the monocycle or bicycle is once or several times substituted,

5 or

R₄ and R₅ together with the nitrogen atom to which they are bound, represent a ring which optionally can be interrupted by a further N atom,

10 said ring can be condensed to a monocycle or bicycle; said ring can optionally be substituted once or several times independently by the residues hydroxy, alkoxy, amino, alkylamino, dialkylamino, nitril or by E-G

15 wherein E represents a valence dash, alkyl, alkenyl, acyl, alkylsulfonyl, sulfonyl, alkylaminocarbonyl, aminocarbonyl, alkoxycarbonyl, oxycarbonyl, alkylaminothiocarbonyl, aminothiocarbonyl which is optionally substituted;

G represents a hydrogen, mono or bicycle, the monocycle or bicycle is optionally once or several times interrupted by heteroatoms and the monocycle or bicycle is once or several times substituted,

20 said monocycle listed in R₁, R₄ and R₅ is a saturated or unsaturated ring systems with 3 - 8, carbon atoms which can optionally be interrupted one or several times by heteroatoms such as nitrogen, oxygen or sulphur,

25 said bicycle listed in R₁, R₄ and R₅ is a condensed bicycle or a bicycle of the type monocycle₁-L-monocycle₂, wherein L denotes a valence dash C₁-C₄-alkyl group, C₂-C₄ an alkenyl group, an oxygen or -C(O)-group,

30 the residues listed under R₁, R₄ and R₅ can optionally be substituted once or several times by halogen, hydroxy, thio, alkyl, hydroxyalkyl, alkoxy, alkylthio, alkylsulfinyl, alkyl-sulfonyl, amino, alkylamino, dialkylamino, nitro, carboxyl, carboxamido, alkoxy-carbonyl, amino or aminocarbonyl optionally substituted once or twice by lower alkyl, nitrile, oxo, thiocarboxamido, alkoxxythiocarbonyl, alkmercaptocarbonyl, phosphono, alkylphosphono, dialkylphosphono, alkylsulfonylamido, arylamino, aryl, hetaryl, aryloxy, arylthio, arylsulfinyl, arylsulfonyl or acyl,

35


pharmacologically acceptable salts, optically active forms thereof or prodrugs thereof.

2. A compound of formula I as claimed in claim 1, in which monocycle denotes for a cyclopentyl, cyclohexyl, cycloheptyl, morpholinyl, thiamorpholinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furyl, thiophenyl, imidazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl or 1,2,4-triazolyl residue.
3. A compound of formula I as claimed in one of the claims 1 or 2, in which bicycle denotes for a naphthyl, tetrahydronaphthyl, dekalinyl, quinolinyl, isoquinolinyl, tetrahydroquino-
linyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, indazolyl, oxindolyl, benzofuranyl, benzothiophenyl, benzthiazolyl, benzoxazolyl, purinyl, biphenyl or (4-phenoxy)phenyl residue and in particular a naphthyl, biphenyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, indolyl or benzimidazolyl residue.
4. A compound of formula I as claimed in one of the claims 1 to 3, in which W of R_1 denotes for a methyl, ethyl, butyl or hexyl residue; V denotes for a phenyl, pyridyl, imidazolyl residue
or
W-V denote for n-Octyl, n-Decyl, Biphenyl or octyl or decyl type residues showing two or three oxygen or biphenyl-type residues showing one or two nitrogen heteroatoms.
5. A compound of formula I as claimed in one of the claims 1 to 4, in which X, Y and Z are all oxygen and R_2 and R_3 are both hydrogen.
6. A compound of formula I as claimed in one of the claims 1 to 5, in which the nitrogen, R_4 and R_5 form a piperazin or piperidin, both of which are substituted at the 4-position.


7. Process for the production of a compounds of formula I of claim 1 wherein in a well-known manner either

a) compounds of the general formula II

5




- 10 in which X, Y, Z, R₁, R₂ and R₃ have the above-mentioned meanings and T represents a leaving group such as Hal or OSO₂R₆, Hal denoting chlorine, bromine or iodine and R₆ denoting an aryl or a methyl residue, are reacted with a compound of the general formula III




- 15 in which R₄ and R₅ have the meanings stated above and are optionally converted into pharmacologically acceptable salts

or

- 20 b) compounds of the general formula IV



- 25 in which R₁, R₄ and R₅ have the above-mentioned meanings, Y and Z independently of one another represent oxygen, sulphur or an NH group and R₇ = methyl, ethyl or phenyl, are reacted with a compound of the general formula V




in which R₂, R₃ and X have the above-mentioned meanings and are optionally converted into pharmacologically acceptable salts

or

in the case that R₄ and/or R₅ represent an acyl, alkylsulfonyl, arylsulfonyl, alkylamino-carbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminothiocarbonyl or arylaminothiocarbonyl residue

c) a compound of the general formula VI



in which X, Y, Z, R₁, R₂ and R₃ have the above-mentioned meanings, is reacted with a compound of the general formula VII or VIII



in which R₈ represents an optionally substituted alkyl or aryl residue, D = C(O), O-C(O), SO₂ or a valency dash, Hal = chlorine, bromine or iodine and A represents oxygen or sulphur

and the compounds obtained are optionally converted into pharmacologically acceptable salts or into optically active forms thereof.

8. Pharmaceutical composition containing at least one compound of formula I as claimed in one of the claims 1 to 6 in addition to common carrier substances and auxiliary substances.

9. Use of compound of formula I as claimed in one of the claims 1 to 6 for the production of pharmaceutical agents having matrix metalloprotease inhibitory action.
- 5 10. Use of compound of formula I as claimed in one of the claims 1 to 6 for the production of pharmaceutical agents having inhibitory action on adamysins.

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/EP 96/05766

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D239/62 C07D239/66 C07D401/04 A61K31/515

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 12 46 743 B (VEB) 10 August 1967 see page 1 - page 4 ---	1
X	DE 763 145 C (DR. RUDOLF GEBAUER, DRESDEN.) 28 December 1944 see page 1 - page 2 --- -/--	1,7-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

28 February 1997

Date of mailing of the international search report

2 0. 03. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

Interr. al Application No
PCT/EP 96/05766

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 98, no. 1, 1983 Columbus, Ohio, US; abstract no. 375z, KNABE, J.: "DERIVATIVES OF BARBITURIC ACIDS." page 40; XP002026400 see abstract	1,7-10
X	& ARCH. PHARM., vol. 315, no. 10, 1982, WEINHEIM, pages 832-839, ---	1,7-10
X	ARZNEIMITTEL FORSCHUNG DRUG RESEARCH., vol. 39, November 1989, AULENDORF DE, pages 1379-1384, XP002026397 J. KNABE: "UNTERSUCHUNGEN ZUR ENANTIOSELEKTIVITÄT VON WIRKSTOFFEN." see page 1379 - page 1383 ---	1,7-10
X	DIE PHARMAZIE, vol. 12, no. 9, September 1957, BERLIN, pages 549-555, XP002026398 H. GOLDHAHN: "ÜBER BARBITURSÄUREN." see page 549 - page 554 ---	1,7-10
X	DIE PHARMAZIE, vol. 25, 1970, BERLIN, pages 64-68, XP002026399 H. USBECK ET AL.: "BEITRÄGE ZUR ANALYTIK VON KALYPNON." see page 64 - page 67 -----	1,7-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/05766

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 1246743 B		NONE	

DE 763145 C		NONE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.